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The Epidermal Growth Factor Receptor (EGFR) is a 170-kilodalton 
transmembrane protein that belongs to the ErbB family of receptor tyrosine 
kinases. Upon ligand-mediated activation, the EGFR is responsible for cell 
growth, proliferation, and tissue homeostasis; however, the EGFR is 
overexpressed in many human malignancies, including MDA-MB-468 cells, a 
metastatic breast epithelial cell line. Studies within this cell line, and other cell 
lines characterized with high EGFR levels, have shown that EGF stimulation 
results in the induction of apoptosis. However, the mechanisms and signaling 
effectors implicated in this process have yet to be elucidated. The overarching 
research goal of this dissertation was to better understand the molecular 
mechanisms employed by the receptor that result in the induction of apoptosis in 
MDA-MB-468 cells. Identifying key regulators/mediators of EGF-induced 
apoptosis will help elucidate new pharmacological targets that better attenuate 
cell growth in cancers characterized by EGFR hyperexpression. 
Through an extensive review of the literature, we have identified Cyclic 
	 vi	
GMP dependent protein kinase (PKG) and Signal Transducer and Activator of 
Transcription 3 (STAT3) as potential signaling intermediates of EGF-induced 
apoptosis. EGF stimulation resulted in a dose-dependent increase in PKG 
activity.  Agonists of PKG did not induce EGFR activation, confirming that PKG 
activity occurred downstream of receptor activation. RNA Interference (RNAi) 
targeting PKG resulted in a significant reduction in EGF-induced cell death, as 
well as a reduction in apoptosis. Similarly, we used siRNA to ablate STAT3 
activity, which resulted in a significant attenuation of apoptosis, as measured by 
PARP cleavage.  Additionally, cytokine-mediated (EGFR-independent) activation 
of STAT3 induced PKG activation, and resulted in a significant induction of 
apoptosis that was sustained over time.  
Together, our results indicate that PKG and STAT3 are molecular targets 
for cancers with high levels of EGFR, and that activation of proteins that induce 
cell death may be more beneficial, therapeutically, than antagonizing proteins 







TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS……………………………………………………………iii 
ABSTRACT …………………………………………………………………………... v 
LIST OF FIGURES ………………………………………………........................... ix 
 
CHAPTERS               PAGE 
I. BACKGROUND AND INTRODUCTION …………………….…... 1 
A. EGFR …………………………………………………….….. 1 
B. Summary of Ceresa Laboratory Preliminary Findings…..12 
C. Cell Death and Apoptosis ………………………………… 14 
D. Protein Kinase G (PKG) ……..………………….………… 20 
E. Signal Transducer and Activator of  
Transcription 3 (STAT3) …….…………………………..... 24 
F. Significance and Statement of Specific Aims…………… 27 
II. MATERIALS AND METHODS …………………………………… 31 
Cell Lines ………………………………………..……………... 31 
Cell Viability Analyses ……………………………….….…….. 32 
Agonists and Antagonists ……………………………….….… 33 
Cell Lysate Preparation and Immunoblot Analyses .……..... 34 
siRNA knockdown in MDA-MB-468 cells……………………. 35 
EGF-Bead Synthesis ………………………………………….. 38 
Statistical Analyses ………………………………….………... 38 
	viii	
III. PROTEIN KINASE G FACILITATES EGFR-MEDIATED  
CELL DEATH IN MDA-MB-468 CELLS……………………….… 40 
 
 Introduction …………………………….…………………….….40 
Results …………………………………………….………..….. 43 
  Discussion ………………………………………………..….… 59 
IV. EGFR-MEDIATED APOPTOSIS VIA STAT3 ………..…….….. 63 
 
  Introduction ……………………………………….…….….….. 63 
  Results ………………………………………….…….……..…. 66 
  Discussion ……………………………………….….…….…... 88 
V. SUMMARY AND FUTURE DIRECTIONS …………..…….…... 95 
A. Restatement of Research Goals …………...…….…...... 95 
B. Summary of Findings …………………..………..……….. 95 
C. Significance of Findings ……………………….…...……. 96 
D. Strengths and Weaknesses …………….…......….…… 102 
1. Strengths ……………………….…..………... 102 
2. Weaknesses ……………………..…….……. 103 
E. Future Directions …………………………..……….….....104 
 
REFERENCES ……………………………………………….……….……. 107 









LIST OF FIGURES 
 
FIGURE            PAGE 
 
1.1 EGFR Domains and Activation………… ……………………………..… 4 
1.2 Differential EGFR endocytic sorting depends on the ligand to which the 
receptor is bound ……………………………………………………........ 11 
1.3 Schematic representation of the intrinsic and extrinsic signaling pathways 
resulting in the induction of apoptosis ………………………………..… 18 
1.4 Schematic representation of intracellular signaling events that result in PKG 
activation ………………………………………………………………….... 22 
1.5 Schematic representation of STAT dimer formation and subsequent 
activation ………………………………………………………………….... 25 
2.1 Compilation of all western blot antibodies employed ………….……… 36 
3.1 Increases in EGF ligand concentration elicit a dose dependent increase in 
      pVASPSer239 phosphorylation in MDA-MB-468 cells …………….….. 44 
3.2 Increases in EGF ligand concentration elicit a dose dependent increase in  
      pVASPSer239 phosphorylation in A431 and HeLa cell lines ………… 47 
3.3 PKG agonists do not elicit EGFR phosphorylation, but do induce dose  
     dependent decreases in MDA-MB-468 cell viability ……………………. 50 
3.4 PKG agonists induce apoptosis in the MDA-MB-468 cell line ………... 53  
3.5 Reduction in PKG activity yields a significant increase in MDA- MB-468 cell  
	x	
viability upon exposure to EGF ligand …………………………………... 55 
3.6 Reduction in PKG activity yields less apoptosis  
in MDA-MB-468 cells ……………………………………………………… 57  
4.1 Phosphorylation of MAPK, SRC, AKT, and BAD in response to high and low  
EGF concentrations ……………………………………………………….. 67 
4.2 STAT3 is tyrosine phosphorylated in response to high, but not low, EGF  
concentrations ……………………………………………………………... 70 
4.3 EGF phosphorylates STAT3 in a dose-dependent manner in MDA-MB-468  
and A431 cell lines ………………………………………………………... 71  
4.4 STAT3 is preferentially upregulated with soluble EGF, and not with EGF-
Beads . ……………..…………………………………………………….... 73 
4.5 EGFR-independent activation of STAT3 promotes apoptosis in MDA-MB-468  
cells …………………………………………………………………………. 75  
4.6 Models of STAT3 Activity and its potential role(s) in EGFR- mediated  
Apoptosis …………………………………………………………………… 77 
4.7 STAT3 inhibitors attenuate cell viability and EGFR activity in MDA-MB-468  
cells ………………………………………………………………………….. 79 
4.8 STAT3 inhibitors attenuate EGFR activity in A431 cells ………………. 81  
4.9 STAT3 inhibitors reduce cell viability in STAT3-null, PC3 cells ………. 84  
4.10 Knockdown of STAT3 attenuates EGFR-mediated apoptosis in  




BACKGROUND AND INTRODUCTION 
 
A.  EGFR  
 
The epidermal growth factor receptor (EGFR) is a cell surface receptor 
that is expressed ubiquitously throughout the body and plays critical roles in 
development and tissue homeostasis.  Further, many cancers are characterized 
by hyperactivated EGFR signaling, either due to overexpression of the receptor 
or somatic activating mutations of the receptor. These perturbations in EGFR 
expression and/or activation are associated with poor patient prognosis. Over the 
last 15-20 years, there has been a concerted effort to develop cancer 
therapeutics that specifically target the aberrant EGFRs, with the goal of 
inhibiting the progression of those cancers. Understanding the basic cell biology 
of the EGFR helps to understand its implications, and define its typical role in 
normal cell biology.  
In order to better understand the function of the EGFR, it is best to start 
with the discovery of one of the principal ligands that initiates its activity. Dr. 
Stanely Cohen isolated and discovered its endogenous ligand, Epidermal Growth 
Factor (EGF) from murine submaxillary glands in the early 1960’s. Frozen 
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submaxillary glands were obtained from mice and homogenized in acetic acid, 
prior to being frozen in a dry ice-alcohol bath. The material was then thawed and 
subjected to a series of ultra-centrifugations at 100,000 x g, and acetic acid 
washes. The newly formed pellet was then subjected to size exclusion, and ion 
exchange chromatography for purification [1]. Amino acid analysis of the purified 
product revealed that EGF is a 53 amino acid residue polypeptide, containing 
three internal disulfide bonds, as depicted in Figure 1.1. 
Dr. Cohen observed that injecting the purified, crude, submaxillary gland 
preparations into newborn mice stimulated growth of embryonic neurons and 
induced precocious eyelid opening.  Having identified a growth factor that was 
able to initiate some very specific physiological responses, the next goal was to 
identify the receptor. In 1978, he and Dr. Graham Carpenter were able to identify 
the presence of the 170-kilodalton EGFR specific for EGF ligand through the use 
of radiolabeled (125 I-labeled) EGF ligand in A-431 cells, a human epidermoid 
carcinoma cell line. They reported increased 32P incorporation in the A-431 cells 
in response to EGF ligand stimulation, suggesting that phosphorylation of EGFR 
components might be critical for its function [2]. In 1982, Dr. Cohen proceeded to 
then successfully isolate and purify the EGFR from A-431 cells, and from normal 
mouse liver cells by means of affinity chromatography. Purification of the 
receptor aided in the confirmation that the EGFR was able to bind 125 I-labeled 
EGF, and that the receptor possessed ligand stimulated, intrinsic kinase activity, 
which was responsible for auto-phosphorylation of tyrosine residues, upon 
binding of EGF. This particular study also confirmed that the receptor in normal
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liver cells had biochemical similarities to receptors found in the carcinoma cell 
line [3]. The contributions of Dr. Cohen and Dr. Carpenter have allowed for 
subsequent studies to unveil further information about the receptor, including its 
physiology, function, and regulation. 
Another huge leap in our understanding of the molecular mechanism of 
EGFR-mediate signaling came in 1984 when Ullrich and colleagues used the 
newly identified tools of molecular biology to clone the human EGFR.  From this 
report, a model (which has been modified numerous times over the years) was 
generated that described the functional domains of the EGFR.  
The EGFR is comprised of three major domains: 1) an extracellular, ligand 
binding domain with cysteine rich regions, 2) a cytosolic, intrinsic kinase domain, 
and 3) a cytosolic domain containing tyrosine residues (Fig 1.1) [4]. Studies by 
Lax et al. devised a method utilizing 125 I-labeled EGF to label the EGFR for 
subsequent isolation, and cleavage through use of Cyanogen Bromide (CNBr). 
Site-specific antibodies were then used to identify certain residues (294 and 543) 
that are critical for the function of the receptor. On the basis of amino acid 
sequence conservation, it was then determined that the extracellular domain is 
comprised of 621 amino acid residues, and could be divided into 4 sub-domains 
[5]. Domains I and III are ligand binding regions, with 37% homology that 
physically bind the ligand. Domains II and IV are rich in cysteine, and have 17% 
amino acid homology that interfaces with other receptors for dimerization [6, 7].   
The model of how these domains come together is based on 




Figure 1.1 EGFR Domains and Activation (Adapated from Brian P. Ceresa). 
The EGFR is comprised of a ligand binding domain, and intracellular kinase 
domain, and a domain containing tyrosine rich region at the cytosol. Ligand 
binding induces a conformational change at the ligand biding domain, which 












































unliganded state, the cysteine-rich domains of a monomeric receptor bind to one 
another through an intramolecular interaction.  Upon the introduction of ligand, 
the receptor undergoes a conformational change such that both ligand binding 
domains bind the ligand and disrupt the interaction between the two cysteine rich 
domains.  The exposure of cysteine rich domain I then can interact with the 
corresponding domain with another EGFR to form a dimer. Ligand binding also 
brings about a conformational change that activates the intrinsic kinase domain, 
which then leads to autotransphosphorylation of the cytosolic tyrosine residues 
(Fig. 1.1) [8]. The kinase domain of each receptor moiety will phosphorylate 
tyrosine residues on its adjacent dimer partner by a conformational change in the 
receptor that places the tyrosine substrate in access to the kinase domain. These 
phosphotyrosines then serve as docking sites for various cytoplasmic enzymes, 
known as effector molecules. By docking to the phosphotyrosines, these 
effectors become activated and modulate various cellular processes that 
contribute to the overall cell biology [9]. Activation of alternative downstream 
signaling cascades by the EGFR induces known responses for cellular 
differentiation, proliferation, migration, and protection from apoptosis [10]. 
Although the EGFR is expressed at the cell surface of many normal cells 
and is critical for animal development and cellular homeostasis, it is often 
mutated and/or hyper-expressed in a number of human malignancies [11]. In a 
study conducted by Real et al., mouse monoclonal antibodies specific for the 
EGFR were used to assess the distribution of the receptor in various human cell 
and tissue types. These studies have confirmed EGFR expression in normal 
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stomach, bladder, colon, esophageal, and lung tissue; however, no expression 
was determined in normal brain tissue or skeletal muscle [12]. In regard to 
malignant cells and tissue, the EGFR has shown to be hyper-expressed in colon, 
kidney, lung and sarcoma cancers; however, it is non-prevalent in primary 
melanoma [12] and gliosarcoma malignancies [13].  
In the analysis of large populations of cancers with EGFR mutations, one 
of the most common mutations entails a deletion of exons 2-7 of the EGFR gene 
that removes virtually the entire extracellular domain of the receptor. In the 
absence of a ligand binding domain or cysteine rich domains that have 
intramolecular binding to prevent dimerization, this receptor is free to associate 
with other mutant receptor and is constitutively active. This mutant receptor is 
referred to as EGFRvIII, and is substantially expressed in patients with 
glioblastoma malignancies [14, 15]. Mutated tyrosine residues of the EGFR at the 
cytosol have also been shown to induce aberrant signaling as well as drug 
resistance in cancers characterized by hyper-expression of the EGFR [16, 17]. In 
addition to the EGFR itself, studies have shown that alterations in EGFR ligand 
expression can hinder certain tissue physiology. Luetteke et al. bred knockout 
mice that lacked endogenous expression of various, endogenous EGFR ligands. 
Pups born to these knockout mice were runted, and showed stunted growth and 
survival. These data provide confirmation of a requirement for EGFR ligands to 
initiate receptor signaling in order for proper development of the mouse 
mammary gland [18]. Overall, it can be inferred that regulation of tyrosine 
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phosphorylation as well as endogenous EGFR ligands are both critical for proper 
signaling and modulation of cellular effects of the activated receptor. 
Numerous cellular processes play a role in controlling EGFR activity. Chief 
among these is ligand-mediated endocytosis. Co-incident with ligand binding to 
the EGFR and activation of the intrinsic kinase domain, the ligand:receptor 
complex is internalized into the cell in either a clathrin-mediated, or clathrin-
independent manner. Clathrin-coated vesicles were first identified in osteocytes 
[19], and then later in neurons [20]. In 1975, Barbara Pearse biochemically 
characterized these clathrin-coated vesicles as transport vesicles upon isolating 
and purifying them from pig brains prior and analyzing their physical properties 
via electron microscopy. She described these vesicles as intracellular vesicles 
with unique “coats” on their cytoplasmic surfaces [21]. Her discovery serves as 
the foundation of biochemical studies entailing clathrin-mediated endocytosis and 
membrane trafficking in general. 
 Sigusmund et al. stimulated receptor activation with EGF for 2 minutes in 
HeLa cells prior to immunostaining and subjecting the fixed cells to 
immunoelectron microscopy. Immunoelectron microscopy allowed for viewing 
and imaging of the immunostained cells in their various compartments during 
EGFR mediated endocytosis [22]. These studies, as well as subsequent studies, 
revealed that Clathrin-mediated EGFR endocytosis is observed at all ligand 
concentrations, where as with higher concentrations of ligand, (10-100 ng/mL) 
the receptor undergoes Clathrin-independent endocytosis via caveole [23, 24].  
	 8	
Once internalized within the cell, the EGFR is subjected to the endocytic 
pathway, a pathway responsible for sorting and determining the ultimate fate of 
the internalized ligand:receptor complex. An intermediate vesicle containing the 
ligand:receptor complex fuses with an early endosome. The mildly acidic 
environment of the early endosome (pH 6) allows certain EGFR ligands (EGF 
and transforming growth factor–alpha (TGFA)) to dissociate from the EGFR, 
should the ultimate fate of the receptor be recycling back to the plasma 
membrane [25]. From here, the unbound-receptor will recycle back to the cell 
membrane via recycling endosomes for additional ligand binding and signaling. 
These recycling endosomes, slightly acidic at pH 6.4, are centered around the 
microtubule-organizing center [26]. These recycling endosomes exhibit tubular-
vesicular morphology, which suggests dynamic trafficking activity and supports 
their involvement with the underlying connection of endocytosis with exocytosis 
[27, 28]. Should the ligand:receptor complex remain inside of the early 
endosome, however, the early endosome will mature into a late endosome with 
the complex intact. The late endosome then fuses with the lysosome just prior to 
the ultimate degradation of the ligand:receptor complex [29]. This endocytic 
pathway is essential for regulating the activity of the EGFR, both temporally and 
spatially. Temporally, meaning that the time it takes the receptor to transverse 
the entire endocytic pathway will ultimately dictate the duration of its signaling. 
Spatially, in regard to the fact that at different subcellular locations, the receptor 
will interact with different effector proteins, activating different signaling cascades 
[30]. 
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Due to hyper-expression of the EGFR in a number of human 
malignancies, including kidney, breast, pancreatic, and cervical cancers [31], the 
correlation between signaling by the EGFR and the endocytic pathway has 
important implications in both receptor tyrosine kinase and cancer biology [30]. 
One approach utilized to assess this correlation involves studying EGFR 
signaling and endocytosis upon activation with different ligands. Currently, there 
are seven identified growth factors that are able to bind to and activate the 
EGFR: these include EGF, amphiregulin (AREG), betacellulin (BTC), epigen 
(EPGN), epiregulin (EREG), heparin-binding EGF-like growth factor (HBEGF), 
and transforming growth factor- α (TGFA) [32]. Although each of these ligands 
stimulate EGFR activation and internalization, they yield diverse effects on 
endocytic sorting [33]. This information can be used advantageously to assess 
the differential effects and regulatory mechanisms different ligands have on 
EGFR signaling. One of the critical components of this dissertation entails 
determining if EGFR ligands have differential effects on EGFR-mediated 
apoptosis. 
EGF is a 53 amino acid, 6.4 kilodalton (kDa) protein that has been shown 
to be involved in regulation of cellular proliferation in mammals [34, 35]. Similarly 
to EGF, TGFA ligand contains 50 amino acids and has a molecular weight of 
approximately 6 kDa. Both EGF and TGFA bind the EGFR however; however, 
TGFA binds with 10-30 fold less affinity to the receptor in rat hepatocytes in 
comparison to EGF. Thoresen et al. isolated hepatocytes from Wistar rats prior to 
stimulating the cells with increasing concentrations of 125 I-EGF and 125 I-TGFA. 
	 10	
Surface binding curves after 24-hour ligand exposure exhibit a binding affinity of 
11.9 nM for TGFA, and 0.42 nM for EGF. The data within this study suggest that 
the two ligands compete for a single population of binding sites in rat 
hepatocytes, although EGF has a significantly higher binding affinity for the 
EGFR than TGFA [36]. It is important to note that TGFA is synthesized and most 
prevalent in cancer cells, and cells transformed by oncogenes and retroviruses 
[37]. BTC, a slightly larger ligand (9 kDa) comprised of 80 amino acids, was 
originally isolated from mouse insulinoma cells, and is able to activate EGFR and 
ErbB4 [38]. Studies utilizing 125 I-BTC in Balb/c 3T3 fibroblasts confirm a binding 
affinity of 0.5 nM for the EGFR, and suggest that the preferred receptor for BTC 
is the EGFR [39]. 
All three of these ligands are able to bind to the EGFR, and stimulate 
kinase activity; however, they differ in regard to their binding affinities to the 
EGFR, and their ultimate fates upon endocytosis and endocytic trafficking (Fig. 
1.2). In order to compare ligand internalization upon EGFR stimulation, 
Roepstorff et al. used an approach of pre-binding various EGFR ligands on ice to 
view the synchronized wave of receptor internalization. After determining optimal 
incubation time using 125 I-EGF, HEp2 cells were incubated with increasing ligand 





Figure 1.2. Model depicting how differential EGFR endocytic sorting 
depends on the ligand to which the receptor is bound (Adapted from 
Roepstorff et al., Traffic, 2009). When bound to HBEGF and BTC ligands, the 
receptor is preferentially targeted for lysosomal degradation. In contrast, AR, EPI, 
and TGFA ligands almost always promote recycling of the EGFR to the plasma 
membrane (PM). EGF stimulation leads to receptor degradation for the majority 





















then determined via FACS analysis. These data report that EGF and BTC 
ligands both target the EGFR for lysosomal degradation. In contrast, TGFA 
almost always promotes recycling of the EGFR to the cell membrane within 90 
minutes of ligand exposure [33]. EGF and BTC can both withstand the acidic 
conditions of the endosomes, dissociating at around pH 5. In contrast, TGFA 
rapidly dissociates from the receptor at pH 7, and is unable to withstand the 
acidic environment of the early endosome. This therefore causes the ligand-free 
receptor to recycle back to the cell membrane [33, 40]. The fate of the EGFR, 
whether it is for degradation or recycling, is critical for its duration of signaling, 
which will can vary based on different ligands bound to the receptor. This has 
ultimate implications in the initiation different signaling cascades. 
B.  Summary of Ceresa Laboratory Preliminary Findings. 
Although the EGFR is typically associated with cell growth and 
proliferation, forms of cancer that hyper-express the receptor often undergo 
EGFR-mediated apoptosis. MDA-MB-468 cells are a metastatic breast epithelial 
cell line, derived from the M.D. Anderson Cancer Center in Houston, Texas [41].  
In this cell line, the EGFR is hyper-expressed, with approximately 1.3 X 106 
receptors per cell [42]. Additionally, this cell line has been documented to 
undergo EGFR-mediated apoptosis [43]. Given these earlier reports of the EGFR 
inducing apoptosis in MDA-MB-468 cells, our lab became interested in further 
elucidating the mechanisms entailed within receptor-mediated apoptosis. 
Because the endocytic pathway is the primary mode of regulating the receptor 
and its duration of signaling, this was logically the best place to begin our studies. 
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Identifying where within the endocytic pathway EGF-induced apoptosis initiated 
might provide some insight in terms of the effectors that were involved in this 
apoptotic mechanism.  
To begin assessing this, polystyrene beads of 0.9-micrometer size, 
covalently conjugated to EGF ligand, were employed. The polystyrene bead itself 
is too large for clathrin-mediated endocytosis; however, the conjugated EGF is 
able to activate the receptor while the bead retains the activated receptor at the 
cell membrane. Hyatt et al. showed that when activated and retained at the cell 
membrane, the EGFR elicits signals for cell growth; however, once internalized 
within the endosomes, the receptor elicits signals for apoptosis, as measured by 
Caspase activity [44]. Subsequent studies within our lab went on to further 
disclose that there is a defect in endocytic trafficking within the MDA-MB-468 cell 
line [44]. Through use of Percoll gradient and indirect immunofluorescence 
assays, Rush et al. showed that instead of traversing the entire endocytic 
pathway to the lysosome for degradation, the EGFR accumulates on the limiting 
membrane of the early endosome in this cell line [45]. These preliminary studies 
set the premise for the work described within this dissertation, which entailed 
furthering our findings by identifying protein effectors with direct implications in 
mediating EGF-induced apoptosis.    
It has been established that the EGFR is a transmembrane tyrosine 
kinase with critical implications in normal cell growth, proliferation, wound 
healing, and tissue homeostasis. It is regulated in both a spatial and a temporal 
manner. Trafficking of the receptor can vary depending on the ligand it is bound 
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to. The EGFR is however hyperexpressed in mammalian cancer [31]. There is 
more known about EGFR cell biology in non-malignant tissue, more than in 
cancer cells. Research has shown that pharmaceutically available EGFR 
inhibitors provided to cancer patients triggers autophagy, a degradative process 
that actually helps cancer cells withstand nutrient-poor conditions [46]. Therefore, 
it is of interest to employ other strategies and therapies, to better attenuate 
malignant cell growth and induce cell death and/or apoptosis.  
 
C.  Cell Death and Apoptosis  
 
 The EGFR is typically associated with cell growth, development and tissue 
homeostasis; however, it has been also known to mediate cell death in cancers 
that hyperexpress EGFRs [43, 47, 48]. Using a cell line that undergoes EGFR-
mediated apoptosis uniquely allows for the enlightenment of the biochemical 
regulation of signaling by using a sensitive, tractable and irreversible readout. 
These findings can be used to better understand other signaling pathways and 
biological responses to cell growth, and its counterpart, programmed cell death.  
The term apoptosis entails the process of programmed cellular death in 
both single-cellular and multicellular organisms. Programmed cell death refers to 
the time and position of cell death during development of a given organism. It has 
many functions during the development process, including adjusting and deleting 
cell numbers [49]. Both apoptosis and programmed cell death are normal 
processes in growth, development and aging as a homeostatic mechanism for 
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proper maintenance of cell populations in tissues [50]. John Kerr first used the 
term apoptosis in 1972, in order to describe a morphologically distinct form of cell 
death. Through the use of light and electron microscopy, morphological events 
that occur during apoptosis have been identified [51]. The process of apoptosis 
entails structural changes that take place in two distinct stages: During stage 
one, the cell rounds in shape, shrinks, and breaks into well-preserved fragment. 
Its nuclear and cytoplasmic compartments condense, causing the cellular 
organelles to become more tightly packed as well as fragmented [50, 52]. 
Pyknosis, or chromatin condensation, is a key characteristic component of 
apoptosis [50]. During the second stage, the apoptotic body, a small sealed 
membrane that is released by cells undergoing programmed cell death [53], is 
taken up by other cells just prior to being degraded and broken down within the 
lysosome [52]. This helps to remove any superfluous material, and provide 
nutrients that were once in the apoptotic cell to the cell that is viable [54].  The 
apoptotic process is a critical component in normal human embryonic 
development, and tissue homeostasis in all living organisms [50, 55]. However, 
cancer cells often have the ability to avoid apoptosis, and continue to proliferate 
[56]. This dysregulation of apoptosis is associated with many malignancies, 
including breast, ovarian and colon cancers [57, 58].  Consequently, this can lead 
to cellular accumulation within a given organism, creating a permissive 
environment for genetic instability and oncogene activation. These events are 
known to disrupt cell turnover and function, as well as damage and kill healthy, 
viable cells [59].  
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Alternatively to apoptosis, cell death can also occur in a necrotic manner. 
Necrosis is considered to be a degradative, toxic process that consequently 
induces cell swelling [60, 61], opposite of apoptosis [60].  Necrosis is an 
uncontrolled process and requires no energy input. It typically affects a large 
population of cells, and causes inflammation, in vivo. Conversely, apoptosis is a 
controlled and energy-dependent process that does not induce inflammation, and 
can occur in individual cells as well as large clusters of cells [50]. The manner of 
cell death by either necrosis or apoptosis depends on the nature of the tissue 
type, its developmental stage, and the cell death signal itself [62]. 
There are several biochemical modifications of apoptotic cells, which can 
be used to help differentiate and identify them. Such modifications include DNA 
breakdown, phagocytic recognition, and protein cleavage and cross-linking [63]. 
The caspase proteins are a family of aspartic acid-specific proteases that have 
proteolytic activity and are major effectors of apoptosis [50, 64]. They are 
normally synthesized as inactive precursors, or pro-enzymes, and only become 
activated upon the induction of apoptosis. The pro-enzymatic form gets cleaved 
and activated by other caspases, initiating a signaling cascade as well as 
apoptosis induction [64]. Currently, there are 14 caspases that have been 
identified [65]. These are categorized into three subgroups based on their 
function within the signaling cascade.  Initiator capsases (caspases 2, 8, 9, and 
10) begin the cascade by activating and cleaving the executioner caspases 
(caspases 3, 6, and 7) at aspartic acid residues. Once executioner caspases are 
activated, they cleave and activate other cellular substrates, such as poly (ADP-
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ribose) polymerase (PARP), which begin the apoptotic process [50, 66]. The third 
subgroup of caspase proteins includes caspases 1, 4 and 5, which have more 
active roles in inflammation [67]. It should be noted however that Caspase-1 has 
been documented to induce PARP cleavage [68], suggesting that PARP 
activation can occur in manners mediated by intrinsic and extrinsic pathways of 
apoptosis.  
Mechanistically, apoptosis is quite complex, involving two main pathways: 
the extrinsic and intrinsic pathways (Fig. 1.3). The extrinsic signaling pathway 
entails initiating apoptosis via transmembrane receptor-mediated interactions. 
These receptors are known as “death receptors”, and are members of the tumor 
necrosis factor (TNF) receptor family [69]. Members of this family have a “death 
domain”, which is a cytoplasmic domain comprised of 80 amino acids. 
The death domain of TNF receptors is primarily responsible for relaying 
signals for cell death from the cell membrane to the intracellular signaling 
pathways [50, 70]. Upon ligand binding, adapter proteins are recruited to the 
death receptors at corresponding death domains. For instance, Fas ligand, a 
ligand with a known biological function of inducing apoptosis [71], binds to the 
Fas receptor, a member of the TNF receptor family. This ligand-receptor 
interaction promotes the intracellular recruitment of the FADD adapter protein 
[72]. FADD then associates with procaspase-8, forming a death-inducing 
signaling complex (DISC). This then results in the auto-catalytic activation of 
caspase-8 from procaspase-8 [73]. The activated caspase-8 then activates 






 Figure 1.3. Schematic representation of the intrinsic and extrinsic 
signaling pathways resulting in the induction of apoptosis (Adapted from 
Elmore et al., Toxicol Pathol., 2007). The intrinsic signaling pathway of apoptosis 
initiates apoptosis in a non-receptor mediated manner, via mitochondrial-initiated 
signaling events. The extrinsic signaling pathway entails initiating apoptosis via 
transmembrane receptor-mediated interactions. Both pathways mediate 























ligand and Fas receptor are causes of various autoimmune diseases. It has been 
shown that upon knocking out the fas gene by homologous recombination, 
generalized lymphoproliferative disease (gld) can be completely recapitulated in 
mouse models [74]. Similarly, gld can be completely cured by simply expressing 
the normal fas gene in the same knockout mice [75]. These studies exhibit how 
critical Fas-induced apoptosis is to the regulation and cellular homeostasis of 
immunocompromised organisms.  
The intrinsic signaling pathway of apoptosis initiates apoptosis in a non-
receptor mediated manner. This pathway entails mitochondrial- initiated events, 
involving certain stimuli that send intracellular signals to act on specific targets 
within the cell. These intercellular signals can be positive or negative signals.  
Negative signals often lead to withdrawal of certain growth factors, which fails to 
suppress death processes and essentially triggers apoptosis. On the other hand, 
positive signals include those for free radicals, toxins, and viral infections [50]. 
Apoptotic signals originating from the cell surface lead to the release of 
cytochrome c from the mitochondria into the cytosol, where it ultimately binds to 
the Apoptotic Protease Activation Factor-1 (Apaf-1). The binding of cytochrome c 
to Apaf-1 initiates apoptosome formation, which catalyzes the activation of 
caspase 9 [50, 76]. Identical to the extrinsic pathway of apoptosis, activation of 
caspase 3 then leads to the downstream induction of apoptosis.  
Apoptosis and programmed cellular death are normal processes within the 
lifespan of the cell. There are key physiological and morphological features that 
distinguish apoptotic cells from necrotic and viable cells. The EGFR is implicated 
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in apoptosis in cell lines that hyperexpress it. Data from the Ceresa laboratory 
indicate that in addition to undergoing EGFR-mediated apoptosis, this apoptotic 
process is spatially regulated within MDA-MB-468 cells. Progression within this 
project involves determining necessary protein components implicated in EGFR-
mediated apoptosis. Through an extensive review of the literature, two candidate 
proteins have emerged as potential signaling intermediates in EGFR-mediated 
apoptosis: Cyclic GMP Dependent Protein Kinase (PKG) and Signal Transducer 
and Activator of Transcription 3 (STAT3). This dissertation describes our findings 
in terms of defining each of their individual roles in EGF-induced apoptosis.  
 
D.  Protein Kinase G (PKG) 
 
Cyclic guanosine monophosphate (cGMP), a second messenger protein 
derived from GTP, elicits downstream signaling events through interactions with 
intracellular receptor proteins. It has implications in the regulation of smooth 
muscle tone, cardiac protection, bone growth, platelet aggregation, and 
regulating apoptosis [77-79] (Fig. 1.4). Nitric Oxide (NO), produced from nitric 
oxide synthase, is the first component involved in the activation of cGMP. NO 
diffuses through the plasma membrane of the cell to activate NO-soluble 
guanylate cyclases, which subsequently increase cGMP levels. Cyclic-GMP then 
proceeds to bind to and activate a number of downstream substrates [78]. One of 
the more prominent receptor substrates of cGMP is the cGMP-dependent protein 
kinase, or Protein Kinase G (PKG). PKG was first discovered in 1970 in the 
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muscle of lobster tails [80]. It is a serine/threonine protein kinase whose 
substrates include receptors, enzymes and ion channels [81] (Fig. 1.4).  
The binding of 2 cGMP molecules is required for the complete activation 
of one PKG molecule [81].  (Fig. 1.4). PKG is a homodimer consisting of two of 
the same monomers, each of which contains a regulatory domain and a catalytic 
domain on one polypeptide chain [77-79, 81]. Dimerization, auto-inhibition, and 
autophosphorylation all occur at the regulatory domain [78]. The catalytic domain  
contains a conserved threonine residue, whose phosphorylation is critical for 
relieving auto-inhibition, and essentially for kinase activity [78, 82]. PKG exists in 
two homologous forms: PKG I and PKG II. PKG I is localized within the 
cytoplasm whereas PKG II is generally associated with the cell membrane [81]. 
Additionally, there are two isoforms of the type I PKG homologue: PKGIβ and 
PKGIα. These two isoforms are closely related, except in the N-terminal domain 
of the PKGIα isoform, which has 16 fewer residues than the PKGIβ isoform [81].  
More recently, the NO/cGMP/PKG pathway has been discovered to play 
critical roles in cell proliferation and chemoresistance in cancer cells [83, 84]. 
Studies have shown that cells that express PKGIα and PKGIβ undergo a 
biphasic response when exposed to NO. A low level of NO result in the specific 
activation of PKGIα, which induces cell proliferation and suppresses the induction
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Figure 1.4. Schematic representation of intracellular signaling events that 
result in PKG activation. Two cGMP molecules must bind to the regulatory 
domain of PKG in order to promote PKG homodimer formation. PKG has a few 
downstream substrates, which include ion channels and pumps, and enzymes 
that regulate intracellular calcium ion concentrations (Wall et.al., PNAS, 2003). 
Ultimately, PKG has been well documented to promote smooth muscle 
relaxation, cardiac protection, platelet disaggregation, as well as regulate 























of apoptosis. This is because the PKGIα isoform has a higher sensitivity to NO 
than the PKGIβ isoform.  Conversely, a high level of NO leads to activation of 
both PKG isoforms, and tends to promote cell apoptosis and suppress cell 
proliferation. It is believed that the activation of PKGIβ by high-level NO 
contributes to the induction of apoptosis in cancer cells [85].  
 There have also been studies correlating EGFR activity and PKG 
activation. When OV2008 cells, an ovarian cancer cell line, were treated with 
increasing EGF ligand concentrations, immunoblot analyses displayed increased 
phosphorylation of serine-239 residue of VASP, a PKG-specific protein substrate. 
Western blot data from this study also exhibit increased phosphorylation of Src, a 
non-receptor tyrosine kinase protein that encodes for the SRC gene. These data 
suggest that activation of the EGFR and subsequent PKG activation occurs in a 
Src-dependent manner [84].  
Recently, activation of PKG by cGMP has become of significant interest  
as a novel molecular tool in the induction of apoptosis in cancer [86]. PKG 
activation has been shown to induce dose dependent decreases in cell viability, 
as well as time dependent increases in caspases 3 and 9 activity within the MDA-
MB-468 cell line. The reduction in cell viability due to PKG activation was 
remarkably rescued with the addition of a PKG-specific antagonist to the MDA-
MB-468 cells [86]. Therefore, it is of interest to explore the activation of PKG and 
subsequent induction of PKG-mediated apoptosis in regard to EGFR-mediated 
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apoptosis. Correlation of these two apoptotic pathways within the MDA-MB-468 
cell line shows potential in identifying a novel protein with direct implications in 
the spatial regulation of the EGFR. 
 
E.  Signal Transducer and Activator of Transcription 3 (STAT3)  
 
Signal Transducer and Activator of Transcription (STAT) proteins were 
initially discovered as a family of cytoplasm-bound transcription factors, which 
mediate normal cellular responses to growth factors, cytokines, and ligands [87, 
88]. STAT activation is critical for the mediation of certain biological processes, 
including cell proliferation, survival, differentiation, development and inflammation 
[89] (Fig. 1.5). To date, there are seven known members of the STAT family 
expressed in mammalian tissue: STAT1, 2, 3, 4, 5a, 5b, and 6. During activation, 
STAT proteins become phosphorylated at their unique critical tyrosine residues 
(Tyr705 for STAT3). This phosphorylation/activation process can be mediated 
directly by growth factor receptor tyrosine kinases [90], or via cytokine receptors  
through Janus Kinase (Jak) mediation [87, 88, 91] (Fig. 1.5). Phosphorylation 
occurs at the cytoplasm, which induces STAT: STAT dimer formation between 
two monomers via SH2 domain interactions. From the cytoplasm, the activated 
STATS accumulate in the nucleus, where they initiate and mediate gene 
transcription by binding to DNA response elements [87]. This results in either 
upregulation or downregulation of the biological processes discussed previously, 





 Figure 1.5. Schematic representation of STAT dimer formation and 
subsequent activation. STAT heterodimer formation and subsequent occurs at 
the cytoplasm, and can occur directly mediated through a receptor tyrosine 
kinase (i.e. EGFR), or conversely, through non-receptor tyrosine kinase 





























Similarly to the EGFR, STAT proteins are implicated in cell growth and 
proliferation; however, they are upregulated in cancers and have been known to 
induce aberrant signaling in cancer cells. STAT3 has been reported to be  
constitutively phosphorylated in human cancer, and has been shown to promote 
tumor survival and cancer cell progression [89, 92].  Constitutive STAT3 activity 
has been reported in 30-60% of primary mammary malignancies [93]. One study 
reports that MDA-MB-468 cells exhibit constitutive activation of STAT3, and that 
upon inhibition using a pharmacological inhibitor (5,15-DPP), STAT3:DNA 
complexes decrease in a dose dependent manner of inhibitor [94]. These finding 
were not observed among the data described within this thesis.  
Prior to being implicated in cancer, STAT3-programmed cellular death 
was found to be associated with and required for IL-6 induced cell death in 
myeloid leukemia [95] and mammary grand involution [96, 97]. After a woman is 
finished lactating, the involution process must occur in order to return the 
mammary gland to normal size of a “pre-pregnancy” state. This process is reliant 
on the post-translational upregulation of STAT3. This leads to downregulation of 
serine protease inhibitor 2A (Spi2A), and upregulation of cathepsin B. This  
upregulation of cathepsin B leads to the ultimate induction of apoptosis from the 
lysosome [98].  
It appears as though STAT3 has been shown to play opposing roles in 
mammary tissue. In one instance, it has been shown to potentiate cell growth 
and invasion when constitutively active in cancer cells. Contrastingly, it has been 
implicated in cell death, being required for mammary gland involution, and even 
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in leukemia. One of the focuses of this dissertation is to define the role of STAT3 
activity in MDA-MB-468 cells. 
It has been established that cGMP dependent protein kinase (PKG) plays 
critical roles in smooth muscle function and regulation. PKG activity has been 
implicated in breast and ovarian cancer. More importantly, PKG activity has been 
shown to induce apoptosis in a dose dependent manner of a PKG agonist in 
MDA-MB-468 cells [99]. Identifying a correlation between PKG-mediated and 
EGFR-mediated apoptosis is therefore of interest for the progression of this 
research project. Additionally, STAT3 has also been implicated in cancer. 
Although this protein is often associated with cell growth and survival, it is 
constitutively active in certain breast cancers, and required for cell death in 
certain contexts, such as post-lactation mammary gland involution [98]. The 
research within the dissertation entails determining if PKG and STAT3 participate 
in the mediation of EGF-induced apoptosis in MDA-MB-468 cells. This 
determination, as well as the identification of the exact role of each effector in this 
biochemical process, has great potential in improving therapeutic treatments that 
target cancers characterized by hyperexpression of receptor tyrosine kinases.  
 
F.  Significance and Statement of Specific Aims  
 
  It has been well established that receptor tyrosine kinases (RTK) inhibitors 
insufficiently attenuate cancer cell growth over prolonged periods of time [100], 
which is due to either acquired or intrinsic resistance of the malignant tissue 
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[101]. Therefore, targeting the employed molecular pathways that promote or 
attenuate EGFR-mediated cell growth may elucidate more efficacious therapeutic 
options for EGFR-associated cancers. Given that EGFR-mediated apoptosis 
occurs preferentially in cells with high-level receptor expression, we elected to 
use this information advantageously by identifying effectors that had direct 
implications in receptor-mediated cell death in a cell line with high EGFR 
expression (MDA-MB-468 cells). We identified PKG and STAT3 as potential 
candidates of EGF-induced mediators of apoptosis in MDA-MB-468 cells. These 
were identified through thorough literature searches, and also through 
preliminary data that exhibited that PKG and STAT3 were both preferentially 
upregulated with high ligand stimulation, stimulation that coincidently induces cell 
death. Therefore, we developed and assessed the following specific aims, and 
their respective hypotheses:  
 
Specific Aim 1: Establish the temporal relationship between the EGFR and 
PKG activity in the induction of apoptosis in MDA-MB-468 cells.  
 
Aim 1A: Determine if PKG-mediated apoptosis is EGFR dependent.  
We hypothesized that EGFR activation induced downstream PKG 
activation, resulting in the induction of apoptosis. To assess this hypothesis, we 
employed RNAi targeting PKG, just prior to activating the EGFR in MDA-MB-468 
cells. Observing an increase in cell viability, coincident with a reduction in 
apoptosis would further support our hypothesis and define PKG is a required 
mediator of EGF-induced apoptosis.  
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Aim 1B: Determine if EGFR-mediated apoptosis is PKG dependent.  
We could not abnegate the possibility that our current hypothesis may be 
incorrect in regard to the sequence of PKG signaling events. In order to address 
this possibility, we elected to assess an alterative hypothesis as well, which was 
that within the MDA-MB-468 cell line, PKG activation signals to the accumulating 
EGFRs at the endosomes, which then results in the induction of apoptosis. To 
assess this hypothesis, we assessed PKG activity within MDA-MB-468 cells 
upon cell stimulation with increasing concentrations of EGF. Further, we intended 
to antagonize EGFR activity via pharmacological inhibition, stimulate of PKG 
activity with PKG agonists before ultimately assessing the outcome on cell 
viability and apoptosis. Observing an increase in cell viability, coincident with a 
reduction in apoptosis would further support our alternative hypothesis and 
define PKG as mediator apoptosis in MDA-MB-468 cells, that functioned via 
EGFR activation. 
 
Specific Aim 2: Determine the role of STAT3 in EGFR-mediated apoptosis 
in MDA-MB-468 cells.  
Similar to our studies entailing PKG, we elected to confirm or refute the 
role of STAT3 in either EGFR-mediated cell growth or cell death. In doing so, we 
antagonized STAT3 activity via pharmacological inhibition and RNAi-induced 
reduction of STAT3 expression. Upon successful STAT3 inhibition and EGFR 
activation, observing a reduction in apoptosis would be indicative of a pro-
apoptotic role of STAT3. On the contrary, enhanced apoptosis accompanied with 
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an enhanced reduced viability would be indicative of a pro-proliferative, 






























  MDA-MB-468, A431, and HeLa cell lines were acquired from the American 
Type Culture Collection (ATCC). PC3 cells were generously gifted from Dr. 
Geoffrey Clark (University of Louisville, Louisville, KY). MDA-MB-468, A431, and 
PC3 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% Fetal Bovine Serum (FBS), 1% penicillin, 1% 
streptomycin, and 2 mM glutamine.  HeLa cells were propagated in similar 
conditions, except with less FBS (5%). The cells were maintained at incubation 
conditions of 37 ºC in 5% CO2. 
 All cell lines were serum starved prior to any experimental procedure. 
Serum deprivation removes proteins and ligands from serum that could introduce 
analytical interference, providing experimental conditions that yield higher 
reproducibility [102, 103]. MDA-MB-468 cells were serum starved overnight in 
serum free (SF) DMEM (unless otherwise specified in figure legends). PC3 and 
HeLa cells were serum starved in SF DMEM for 2 hours prior to beginning of all 
experiments. All reagent treatments for MDA-MB-468, HeLa and PC3 cell lines 
were prepared in SF DMEM. Preliminary data in the A431 cell line exhibited that 
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A431 cells do not retain viability in SF DMEM over prolonged periods of time. 
Therefore, A431 cells were always serum “starved” in reduced serum, DMEM 
supplemented with 1.25% FBS. A431 cells were subjected to reduced serum for 
2 hours prior to beginning all experimental procedures.  All reagent treatments for 
A431 cell lines were prepared in DMEM supplemented with 1.25% FBS. 
 
Cell Viability Analyses 
1. MTT assay 
MTT assays were conducted in order to assess cell viability of MDA-MB-
468-cells upon exposure to agonists of PKG. The MTT assay assesses 
mitochondrial dehydrogenase activity based on its ability to cleave the 
tetrazolium ring of the MTT reagent (Sigma Aldrich), and subsequently produce 
formazan. Only mitochondria of viable cells are capable of such cleavage. Cells 
were plated at a density of 5,000-10,000 cells with DMEM supplemented with 
10% FBS in a 96 well plate. After a 24-hour incubation period, the cells were 
washed with PBS and serum starved for 3 hours in DMEM supplemented with 
0.2% BSA. The cells were then treated with various ligands and reagents in order 
to induce cell death.  After appropriate incubation periods, the MTT reagent (5 
mg/mL in PBS) was added to each sample within the 96-well plate. The cells 
were then incubated for 2 hours at 37ºC in the absence of CO2.  An extraction 
buffer (20% sodium dodecyl sulfate, 50% N-dimethylformamide, 50% ddH2O, 
80% Acetic Acid, 1M HCl) was then added to all samples of the 96-well plate in 
order to extract and solubilize the formazan crystals. After an additional 30-
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minute incubation with extraction buffer at 37ºC in the absence of CO2, the 96-
well plate was then analyzed on a BioTek Synergy HT plate reader and Gen5 
BioTek software, at a wavelength of 570 nm. 
2. Alamar Blue Assay 
Alamar Blue assays were also conducted in order to assess cell viability 
within the MDA-MB-468 cells. Resazurin, the active ingredient in the alamarblue 
reagent, is reduced to Resorufin in viable cells. Resorufin is highly fluorescent 
and viable cells enhance this fluorescence, which can be analyzed and quantified 
on a plate reader.  Cells were plated at a density of 10,000 cells in DMEM 
supplemented with 10% FBS in a 96-well plate. After a 24-hour incubation 
period, the cells were washed with PBS and subjected to serum starvation 
conditions described in the previous section. The cells were then treated with 
reagents in order to induce either cell growth or death. The cells were then 
incubated in the presence of the various reagents for 24-48 hours. The Alamar 
Blue reagent was then added as 10% of the sample volume prior to a 2-hour 
incubation period. The 96-well plate was then analyzed for fluorescence on a 
BioTek Synergy HT plate reader and Gen5 BioTek software, at wavelengths of 
530 nm (excitation) and 590 nm (emission). 
 
Agonists and Antagonists 
 
 The following agonists of PKG were employed in the research 
summarized in Chapter III: 8-Bromoguanosine 3',5'-cyclic monophosphate (8-Br-
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cGMP; Sigma-Aldrich, St. Louis, MO), 8-(4-Chlorophenylthio)-guanosine 3′,5′-
cyclic monophosphate (8-pCPT-cGMP; Biolog Life Science Institute, Bremen, 
Germany), and 8- (4- Chlorophenylthio)guanosine- 3', 5'- cyclic monophosphate, 
acetoxymethyl ester (8-pCPT-cGMP-AM; Biolog Life Science Institute, Bremen, 
Germany).  
STAT3 antagonists, Stattic and S3I-201, were both acquired from Sigma-
Aldrich, and were employed at concentrations specified in the figure legends. 
The Oncostatin M (OSM) cytokine was employed as a STAT3 agonist, and was 
acquired from PeproTech (Rocky Hill, NJ). EGF ligand was acquired from 
ProSpec Protein Specialist (East Brunswick, NJ). Staurosporine (STS) was used 
as a positive control for apoptosis, and was acquired from Sigma-Aldrich. 
 
Cell Lysate Preparation and Immunoblot Analyses.  
 
Cell lysates were acquired by washing the cells twice in PBS prior to the 
equilibration to 4 ºC and addition of RIPA lysis buffer for cell solubilization (150 
mm NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mm Tris (pH 
8.0), 10 mm sodium pyrophosphate, 100 mm sodium fluoride, 2 mm 
phenylmethyl sulfonyl fluoride). The lysis buffer/cell mixture was then rotated 
end-over-end for 10 min at 4 °C, followed by a 10 minute centrifugation period at 
15,000 x g, at 4 °C. The protein concentration of the supernatant from each 
sample was then assessed by a BCA assay (Pierce), and samples were 
subjected to a 1:3 dilution in SDS sample buffer. Equivalent amounts of protein 
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(20-60 µg) were separated by a 10%, 12%, or 15% SDS-PAGE, prior to be being 
transferred to nitrocellulose membranes. After being washed in a blocking 
reagent to prevent non-specific antibody binding, the membranes were exposed 
to various primary antibodies overnight at 4 ºC (All antibodies used are listed in 
Table 2.1). After a 1-hour incubation period with HRP-conjugated secondary 
antibodies, the membranes were washed in TBS-Tween and visualized by ECL 
reagent using a Fotodyne imaging system. All western blot data were analyzed 
and quantified using ImageJ software. 
 
siRNA knockdown in MDA-MB-468 cells 
 
 Small Interfering RNA (siRNA) targeting PKG-I was acquired from 
Dharmacon (Lafayette, CO). Two siRNA oligonucleotides targeting STAT3 (5’-
GGAGAAGCAUCGUGAGUGA-3’) (5’- CCAUUUGGUGUUUCAUAA-3’) were 
also acquired from Dharmacon. Scramble control siRNA (siCON) was acquired 
from IDITDNA (Coralville, IA). MDA-MB-468 cells were treated with final 
concentrations of 200 nM PKG siRNA, 200 nM STAT3 siRNA or 200 nM siCON 
along with INTERFERin (Polyplus Transfection, Strasbourg, France). Cells were 
exposed to PKG siRNA for 96 hours and STAT3 siRNA for 72 hours. Cells were 
then treated with EGF or STS for maximal time points of 24 or 48 hours, 
coincident with maximal siRNA exposure of either 96 hours (for PKGI siRNA) or 
72 hours (for STAT3 siRNA). Details of each experiment and subsequent 












































































































































































containing the respective experiment. Knockdown efficiencies were calculated to 
be 55% for PKG siRNA, and 78% for STAT3 siRNA. 
 
EGF-Bead Synthesis 
 Polystyrene beads of 0.9 µM size (Sigma) were covalently conjugated to 
recombinant human EGF (Invitorgen) as previously described [104]. In short, 
EGF molecules are conjugated to carboxylate modified, polystyrene beads via 
zero length crosslinker, N-(3-Dimethylaminopropyl)-N’-ethylcarbodimide 
hydrochlorine (EDAC; Sigma). After rigorous washing, the EGF-beads were 
reconstituted and stored in PBS and glycerol. The beads were stored at -20ºC 




 Treatment groups within each Alamarblue experiment were quantified to 
either untreated or vehicle controls in order to generate percent viabilities for 
each experimental condition. These percentages for 3 to 4 individual experiments 
were then averaged together. Data acquired from both assays are reported as 
the means of the percent viabilities ± standard error mean (SEM; n=3).  An 
unpaired student t-test was then performed for the determination of significance. 
Each treatment group was compared to the untreated, serum free (SF), DMEM 
control. For the data within Chapter III, Protein Kinase G facilitates EGFR-
Mediated Cell Death in MDA-MB-468 Cells, a p value of less than 0.1 is 
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designated significant, and is indicated by a single asterisk (*). A p value of less 
than 0.05 is designated significant, and is indicated by two asterisks (**). A p 
value of less than 0.001 is designated very significant, and is indicated by three 
asterisks (***). A p value of less than 0.001 is designated extremely significant, 
and is indicated by four asterisks (****). Within Chapter IV, A p value of less than 
0.05 is designated significant, and is indicated by a single asterisk (*). A p value 
of less than 0.01 is designated significant, and is indicated by two asterisks (**). 
A p value of less than 0.001 is designated very significant, and is indicated by 
three asterisks (***). A p value of less than 0.0001 is designated extremely 



















PROTEIN KINASE G FACILITATES EGFR-MEDIATED 




The Epidermal Growth Factor Receptor (EGFR) is a cell surface receptor 
that is expressed in almost every tissue of the body, and plays critical roles in 
development and tissue homeostasis [8, 105]. In addition to these physiological 
roles, many cancers, such as lung [106], breast [43], and colon [107] 
malignancies, are characterized by hyper-activated EGFR signaling, either due 
to overexpression of the receptor or somatic activating mutations of the receptor 
[43, 47]. Perturbations in EGFR expression and/or activation are associated with 
poor patient prognosis. There are a number of FDA-approved therapies that 
target the EGFR and attenuate cancer growth. These include small molecular 
inhibitors such as Erlotinib and Gefitinib, which has been approved for treatment 
of lung [17] and colon [108] cancers, and humanized monoclonal antibodies 




Despite the progress in using EGFR inhibitors as a mode of cancer 
treatment, these therapies are not failsafe. These drugs can have off-target 
effects (i.e. dermatitis, colitis, and corneal erosions) and some cancers become 
refractory to the drugs over time [110-112]. EGFR inhibition can also trigger 
autophagy in cancer cells, a degradative process that actually helps cancer cells 
withstand nutrient-poor conditions [46]. Thus, despite the therapeutic benefits of 
EGFR-inhibition, there remains a need for more aggressive and/or targeted 
treatments that will arrest cancer growth and progression. 
A more comprehensive understanding of how EGFR signaling is regulated 
will facilitate the design of new agents. We hypothesize that one key to new 
therapies might lie within the cell itself. Paradoxically, cells that overexpress the 
EGFR naturally (i.e. A431 and MDA-MB-468 cells [113, 114]) or through 
bioengineering [115], undergo apoptosis in response to EGF treatment. By 
utilizing this endogenous signaling mechanism we predict that this will specifically 
target EGFR-overexpressing cells with minimal side effects to healthy cells. 
However, to most effectively utilize these pathways, we need to fully understand 
the mechanisms that regulate their signaling.  
The goal of this study was to determine the signaling events that occur 
downstream of EGFR activation that lead to apoptosis. By determining how 
EGFR-mediated apoptosis occurs in cell lines that overexpress the EGFR, we 
predict this pathway can be used to halt cancers that express high levels of 
EGFR. These studies were conducted primarily in MDA-MB-468 cell line, a 
metastatic, breast, epithelial cell line [41]. These cells express approximately 1.3 
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X 106 EGFR per cell [42], and have a well documented induction of apoptosis in 
response to EGF ligand (≥ 10 ng/mL) [43]   
One candidate regulator of EGFR-mediated apoptosis is Cyclic guanosine 
monophosphate (cGMP)-dependent protein kinase (PKG). PKG exists in two 
functionally indistinguishable forms: PKG I and PKG II. PKG I is localized within 
the cytoplasm whereas PKG II is generally associated with the cell membrane 
[81]. Additionally, there are two isoforms of the type I PKG homologue: PKGIβ 
and PKGIα. These two isoforms are closely related, except in the N-terminal 
domain of the PKGIα isoform, which has 16 fewer residues than the PKGIβ 
isoform [81]. PKG1 has been demonstrated to be sufficient to induce apoptosis in 
MDA-MB-468 cells [99].   PKG is activated by cGMP, a second messenger 
produced by the conversion of GTP by guanylyl cyclase (Fig. 1.4). PKG mediates 
downstream signaling through interactions with intracellular phosphoproteins 
[116], including VASP [117] and Phosphodiesterase type 5 (PDE5) [118]. The 
activity of these proteins includes regulating smooth muscle tone, bone growth, 
platelet aggregation, and electrolyte and fluid homeostasis. [77-79].  
Given that stimulation of PKGI but not PKGII was sufficient to induce 
apoptosis [86], we developed the hypothesis that the EGFR mediates apoptosis 
though PKGI activity. We find that MDA-MB-468 cells have a reduction in cell 
viability and an increase in apoptosis in response to both EGF and PKG 
agonists. Further, stimulation of the EGFR leads to enhanced PKG activity in 
MDA-MB-468, A431, and HeLa cell lines, as measured by Vasodilator Stimulated 
Phosphoprotein (VASP) phosphorylation. PKG stimulation does not enhance 
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EGFR phosphorylation in MDA-MB-468 cells, indicative that PKG is downstream 
of the EGFR. Further, knock down of PKG decreases the dose dependent 
EGFR-mediated cell viability and reduces apoptotic pathways. From these data, 
we conclude that in MDA-MB-468 cells, the EGFR utilizes PKG to promote cell 
death via apoptotic pathways.  
Results 
It is well documented that cell lines that hyperexpress the EGFR, such as 
MDA-MB-468 cells [43, 119, 120], undergo EGFR-mediated apoptosis. This is 
demonstrated with the dose-dependent decrease in MDA-MB-468 cell viability 
(Fig 3.1A). How a mitogenic growth factor receptor mediates cell death has 
studied for a number of years, with no clear resolution of the molecular 
mechanism. Determining the effectors that are necessary for EGFR-mediated 
apoptosis is a critical first step understanding the underlying molecular 
mechanism.   
Based on previous studies linking Protein kinase G (PKG) activity to 
apoptosis in MDA-MB-468 cells, we tested whether PKG was downstream of 
EGFR activity (Fig 3.1B). Following treatment with EGF, there was a dose-
dependent increase in EGFR phosphorylation [measured as a function of 
phosphorylation of tyrosine 1045 (pY1045)] (Fig. 3.1C). Active PKG 
phosphorylates VASP specifically at Serine239 [121]; serine phosphorylation of 
VASP is accompanied by a slowed electrophoretic mobility of the protein on 
SDS-PAGE resulting in two bands on both phosphorylated VASP (pVASP) and 















Figure 3.1. Increases in EGF ligand concentration elicit a dose dependent 
increase in pVASPSer239 phosphorylation in MDA-MB-468 cells. A. MDA-
MB-468 cells were seeded into 96-well dishes prior to being serum starved 
overnight. The cells were treated for 48 hours prior to AlamarBlue, cell viability 
analyses. Data are reported as the mean ± SEM (n=3). B. Serum-starved MDA-
MB-468 cells were treated with varying concentrations of EGF (0, 0.16, 0.5, 1.6, 
5 and 16 nM) for 30 minutes. Cell lysates were prepared, and equivalent 
amounts of protein (20 µg) were resolved by 12% SDS-PAGE and transferred to 
nitrocellulose. Membranes were probed for EGFR phosphorylated at tyrosine 
1045 (pY1045), total EGFR (EGFR), VASP phosphorylated at serine 239 
(pVASP), total VASP (VASP), and GAPDH as a loading control. Quantification of 
EGFR phosphorylation (pY1045) (C.) and VASP phosphorylation (pVASP) (D.) 
immunoblots using ImageJ software. Data are plotted as the mean ± Standard 










Using a phosphoVASP immunoblot to monitor activation of PKG, we found 
that, co-incident with receptor phosphorylation, there was a dose-dependent 
increase in PKG activity (Fig 3.1B). Comparison of the EC50 of EGF-mediated 
EGFR and VASP phosphorylation (4.7 nM and 0.49 nM, respectively) indicates 
that the processes are tightly coupled; only low levels of EGFR activity are 
needed to stimulate PKG.  
EGFR:PKG communication is not unique to MDA-MB-468 cells [84]. A431 
cells are a metastatic epidermoid cell line that also undergoes EGF-dependent 
apoptosis [120], and hyperexpresses EGFRs at levels (1.5 x 106 EGFR/cell 
[125]) comparable to MDA-MB-468 [42]. When treated with EGF, A431 cells had 
a similar dose-dependent induction of EGFR and VASP activity (Fig. 3.2A). EGF 
induced EGFR phosphorylation in A431 cells with a similar efficacy and potency 
as seen in MDA-MB-468 cells (Fig. 3.2B). A431 and MDA-MB-468 cells had 
comparable levels of pVASP activity (~2-3-fold over basal), and comparable 
EC50’s to stimulate pVASP (0.56 nM and 0.66 nM, respectively). Further, in HeLa 
cells that expresses much lower levels of EGFR (~50,000 EGFRs/cells [126], 
despite a smaller dynamic range of EGFR phosphorylation (Fig. 3.2D), the EC50 
was comparable (0.66 nM). Thus, in multiple EGFR-expressing cell lines, there 
was an EGF-dependent PKG activation. 
Having established that EGFR could activate PKG, we wanted to 
determine if direct activation of PKG was sufficient to induce cell death. MDA-
MB-468 cells were treated with three commercially available agonists of PKG – 











Figure 3.2. Increases in EGF ligand concentration elicit a dose dependent 
increase in pVASPSer239 phosphorylation in A431 and HeLa cell lines. 
A. A dose response was conducted in A431 cells using 0, 0.16, 0.5, 1.6, 5 and 
16 nM concentrations of EGF ligand. Cells were serum starved for 2 hours, and 
then exposed to the various ligand concentrations for 60 minutes. Forty µg of 
protein per sample were then resolved on a 10% SDS-PAGE. Western blot data 
of pY1045 (B.) and pVASPSer239 (C.) from three independent dose response 
experiments in A431 cells were quantified to blots of total protein (EGFR and 
VASP, respectively) using ImageJ software. Error bars are expressed as ± SEM. 
D. A dose response was conducted in HeLa cells using 0, 0.16, 1.6 and 16 nM 
concentrations of EGF ligand. Cells were serum starved for 2 hours, and then 
exposed to the various ligand concentrations for 60 minutes. HeLa cell lysates 
(60 µg) were then resolved on a 10% SDS-PAGE. Western blot data of pY1045 
(E.) and pVASPSer239 (F.) from three independent dose response experiments 
in HeLa cells were quantified to blots of total protein (EGFR and VASP, 









8-(4-Chlorophenylthio)-guanosine 3′,5′-cyclic monophosphate (8-pCPT-cGMP), 
and 8- (4- Chlorophenylthio) guanosine- 3',5'- cyclic monophosphate, 
acetoxymethyl ester (8-pCPT-cGMP-AM). 8-Br-cGMP is a brominated derivative 
cGMP analog and is cell permeant [127]. 8-pCPT-cGMP and 8-pCPT-cGMP-AM 
are both PKG agonists that only differ by the presence of an acetoxymethyl ester; 
the addition of the acetoxymethyl ester makes 8-pCPT-cGMP-AM more cell 
permeant, and resistant to metabolic turnover [128]. MDA-MB-468 cells were 
treated with varying concentrations of these compounds and found to activate 
PKG (measured by VASP phosphorylation) (Figs. 3.3A and 3.3B), treatment with 
8-pCPT-cGMP did not produce detectable levels of pVASP, likely due to limited 
cell permeability, and was not used in cell viability experiments. Importantly, none 
of the PKG activators were able to induce detectable levels of EGFR 
phosphorylation (Figs. 3.3A and 3.3B). Next, the effect of the PKG agonists on 
cell viability was examined. Both 8-Br-cGMP and 8-pCPT-cGMP-AM caused a 
modest, dose-dependent decrease in cell viability (Figs. 3.3C and 3.3D).  
 To determine if the observed decreases in cell viability were a 
consequence of apoptosis, we examined caspase-3 and poly ADP-ribose 
polymerase (PARP) cleavage via immunoblot analysis. Caspase-3 is a critical 
executioner of apoptosis [129]; when active, executioner caspases cleave and 
activate various substrates, such as poly ADP-ribose polymerase (PARP), which 
ultimately cause the morphological changes associated with apoptotic cells [50, 













Figure 3.3. PKG agonists do not elicit EGFR phosphorylation, but do 
induce dose dependent decreases in MDA-MB-468 cell viability. A. The PKG 
agonist, 8-Br- cGMP, was used at 0.1, 0.3, 1, 1.3, 2 and 3 mM concentrations. 
This treatment was accompanied with a positive control for EGFR 
phosphorylation, 16 nM EGF. The cells were exposed to the various conditions 
for 1 hour prior to the harvesting of each cell lysate. Forty µg of protein per 
sample were then resolved on a 12% SDS-PAGE. B. The PKG agonist, 8-pCPT-
cGMP-AM (8-p-AM), was employed at 1, 10, and 100 µM concentrations. The 
other PKG agonist in use, 8-pCPT-cGMP, was employed at 100, 250, and 500 
µM concentrations. Cells treated with serum free DMEM (SF) served as a 
negative control for both pVASP and EGFR phosphorylation. Cells treated with 
16 nM EGF served as a positive control for EGFR and pVASP-SER239 
phosphorylation. C. Results from an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) cell viability assay. Cells were serum starved 
overnight, and then subjected to each experimental condition for 48 hours total 
prior to MTT analyses. A vehicle control of 6.7% deionized water in DMEM was 
used to accompany the 3 mM 8-Br-cGMP treatment. Data are expressed as 
means of percent viability ± SEM (n=3). D. Results from an AlamarBlue cell 
viability assay. Cells were serum starved overnight, and then subjected to each 
experimental condition for 48 hours total prior to AlamarBlue analyses. Cells 
treated with the PKG agonist, 8-p-AM, were quantified to their respective vehicle 
control (cells treated with 0.2% DMF). All other data were quantified to the serum 
free control. All data are plotted as the average of percent viability ± SEM (n=4).  
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(8-p-AM) and 16 nM EGF. Cells were collected and analyzed by immunoblot for 
the presence of cleaved PARP and caspase 3 (Fig. 3.4). Cells were incubated in 
serum free media (SF) and vehicle alone as a negative control and with 
Staurosporine (STS) as a positive control. The PKG activators and EGF induced 
PARP and caspase-3 cleavage (Fig. 3.4A). Consistent with the cell viability 
assays, EGF treatment was more effective than PKG activation (Figs. 3.4B and 
3.4C). 
Finally, to determine if PKG is a signaling intermediate in EGFR-mediated 
apoptosis, we examined EGFR-mediated signaling with attenuated PKG 
expression (Fig. 3.5). Cells were transfected with control (siCON) or PKG specific 
siRNA, treated with EGF for 24 or 48 hours, and assayed for cell viability (Figs. 
3.5A and 3.5B). PKG knockdown was verified by immunoblot (Fig 3.5C) and was 
quantified using Image J software to be 55%, consistent with previous reports 
[130]. In the absence of PKG, EGF treatment was not as effective at decreasing 
cell viability. This was statistically significant after 48 hours of EGF treatment and 
at high EGF doses (i.e. 16 nM), however, this trend is observed at all three EGF 
concentrations. When PKG knock down cells were treated with EGF, there was a 
trend of reduced activity in apoptotic markers (PARP and Caspase-3 cleavage) 


















Figure 3.4. PKG agonists induce apoptosis in the MDA-MB-468 cell line.  
A. MDA-MB-468 cells were serum starved overnight. With the exception of 
Staurosproine (STS), the cells were then subjected to each experimental 
condition for 24 hours. MDA-MB-468 cells were treated with STS for 3 hours prior 
to being harvested. This was done in order to induce a robust response without 
inducing catastrophic damage to the cell. The induction of apoptosis was 
determined by using PARP and Cleaved Caspase-3 antibodies. With the 
exception of STS, 40 µg of protein per sample were then resolved on a 15% 
SDS-PAGE. Fifteen µg of protein from the STS sample were resolved on the 
15% SDS-PAGE. This was done in order to ensure that our positive control was 
within the dynamic range. Quantification of western blot data from cleaved PARP 
(B.) and Caspase-3 (C.) from three independent experiments. Band intensities 
were determined using Image J software and plotted relative to total PARP (% 
cleaved PARP) or GAPDH (ratio of cleaved Caspase-3/GAPDH), respectively. 








Figure 3.5. Reduction in PKG activity yields a significant increase in MDA-
MB-468 cell viability upon exposure to EGF ligand. MDA-MB-468 cells were 
subjected to either 200 nM control siRNA (siCON) or 200 nM of siRNA targeting 
PKG for a total of 96 hours. The day after initial siRNA transfection, MDA-MB-
468 cells were seeded into 96-well dishes and were then subjected to various 
concentrations of EGF ligand for either 24 hours (A) or 48 hours (B). Data are 
plotted as the average of percent viability ± SEM (n=3) C. Representative 
western blot image of 200 nM siCON and 200 nM PKG siRNA exposed MDA-
MB-468 cells at 96 hours. Cell lysates were loaded in volumes of decreasing 
protein concentration (20, 10, and 5 µg) and then resolved on a 12% SDS-PAGE. 
Blots were then quantified using ImageJ software in order to determine the 

























Figure 3.6. Reduction in PKG activity yields less apoptosis in MDA-MB-468 
cells. A. Representative western blot image of 200 nM siCON and 200 nM PKG 
siRNA exposed MDA-MB-468 cells at 96 hours. Cell lysates were loaded in 
volumes of decreasing protein concentration (20, 10, and 5 µg) and then 
resolved on a 12% SDS-PAGE. Blots were then quantified using ImageJ 
software in order to determine the percentage of PKG knockdown (55%). B. 
Representative western blot image of western blot analyses of PKG knockdown 
and siCON MDA-MB-468 cells. Cells were treated with 200 nM siCON or 200 nM 
PKG siRNA for 96 hours. The cells were also exposed to either serum free media 
(SF), EGF, or Staurosporine (STS) for 48 hours. Cell lysates were then 
harvested and resolved on a 15% SDS PAGE. Immunoblot images for PARP and 
Cleaved Caspase-3 were used as indicators of apoptosis. Quantification of 
western blot data from cleaved PARP (C.) and Caspase-3 (D.) from three 
independent experiments. Band intensities were determined using Image J 
software and plotted relative to total PARP (% cleaved PARP) or GAPDH (ratio 











The purpose of this study was to identify effectors downstream of EGFR 
activation that are actively mediating apoptosis in MDA-MB-468 cells. Using a 
combination of immunoblot assays, pharmacological activators, and RNAi, we 
tested the hypothesis that the EGFR is signaling via PKG to induce apoptosis. 
The ligand-dependent activation of the EGFR corresponded with phosphorylation 
of the PKG substrate VASP (Fig. 3.1B). The directionality of this signaling was 
confirmed by the observation that direct activation of PKG with the agonists 8-Br-
cGMP and 8-p-AM (Figs. 3.3A and 3.3B) failed to stimulate the EGFR. Finally, 
when PKG was knocked down, there was a statistically significant reduction in 
EGFR-mediated cell viability and a decrease in caspase-3 cleavage. 
PKG is not normally associated with a downstream effector of the EGFR. 
However, it is not unprecedented; EGF stimulation in an ovarian cancer cell line, 
OV2008, leads to an EGFR-dependent VASP phosphorylation as well [84]. In 
addition to MDA-MB-468 cells, EGF treatment of A431 and HeLa cells, leads to a 
dose-dependent induction of phosphoVASP (Fig. 3.2). It should be noted that in 
cell lines which express physiological levels of EGFR, exposure to higher levels 
of ligand often elicit total receptor degradation [44] (Fig. 3.2D). EGFR:PKG 
communication can occur independent of receptor expression. However, the 
cytotoxicity associated with EGFR-mediated PKG activity may be a function of 
the kinase’s subcellular distribution, the duration of receptor:effector 
communication, or the presence of downstream substrates.  
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While A431 cells undergo EGFR-mediated apoptosis [120, 131], EGF is 
not as potent in its induction of apoptosis as what has been observed in MDA-
MB-468 cells. For instance, it has been reported that A431 cells are capable of 
surviving EGF treatment for several days, and can become resistant to the 
induction of apoptosis in the presence of EGF [132]. Further, the initial reports of 
PKG-mediated apoptosis were in MDA-MB-468 cells [86, 99]. We therefore 
elected to pursue subsequent experiments in a cell line with the greatest dynamic 
range. 
PKG activity is often associated with cytoprotective biology (i.e. heart cells 
[133], neurons, and glia cells [134, 135]) rather than a mediator of apoptosis. 
However, there is other evidence linking PKG to other proapoptotic effects in 
breast [86], ovarian [84], and colon cancer. Activation of PKGI in colon cancer 
cells induces apoptosis in a c-Jun NH2 NH2-terminal kinase 1 (JNK1) pathway 
dependent manner [136]. Many of the roles of cGMP and PKG signaling are well 
understood; however, a lack of clarity remains in terms of the role of PKG in 
cancer. This research aims to provide more information about PKG and it’s 
association with EGFR, and other receptor tyrosine kinases with implications in 
human malignancies. 
By most accounts, apoptosis is an aberrant EGFR-mediated signaling 
event for a receptor that typical promotes cell growth. It is a challenge to decipher 
the molecular events that specifically promote apoptosis in the context of 
receptor- and cell stress-mediated pro-growth signaling. As a result, the 
molecular details of EGFR-mediated apoptosis remain controversial. The signal 
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transducers and activators of transcription (STAT) pathway is one of the most 
intensively studied mechanism entailed in EGFR-mediated apoptosis in cancer 
[137]. Studies have shown that in cell lines that hyper-express EGFR, the EGFR 
activates STAT1, which recognizes responsive elements of and upregulates p21 
[138, 139]. When active, p21 is a cyclin-dependent kinase inhibitor that 
suppresses reduces cell proliferation and induces apoptosis [140]. More recent 
studies have shown that in cell lines with elevated EGFR expression, EGF 
stimulation suppresses activity within the phosphoinositide 3-kinase/protein 
kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway, 
suggesting that inhibition of the PI3K/AKT/mTOR pathway might be required for 
EGFR-mediated apoptosis to occur [141].  
This report provides data indicating that in MDA-MB-468 cells, PKG 
contributes to EGFR-mediated cell death, likely through apoptotic signaling 
pathways. Although the contribution of PKG to EGFR-mediated apoptosis 
appears modest, this is likely a consequence of partial PKG knock down (~55% 
knock down). It remains unclear how a mitogenic growth factor receptor and a 
cytoprotective effector collaborate to induce apoptosis. One possible explanation 
is that hyperstimulation of cell viability pathways leads to cell catastrophe over 
time. Several pieces of evidence support this model. First, cell lines that have low 
levels of EGFR and more rapid receptor turnover do not induce apoptosis [45]. 
Second, low levels of EGF ligand do not induce MDA-MDA-468 cell apoptosis 
[43]. Third, the slowed kinetics of cell death following EGFR or PKG activation 
argue that the induction of apoptosis does not occur as a direct activation of an 
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enzymatic pathway. Nevertheless, the EGFR:PKG communication shows 
promise as a new pathway for selectively mediating cytotoxicity in cells that 










The Epidermal Growth Factor Receptor (EGFR) is a transmembrane 
receptor tyrosine kinase that plays critical roles in cell growth, tissue 
development, and overall cellular homeostasis [8, 105]. Despite these critical 
physiological roles, there are a myriad of human malignancies [43, 106, 107] that 
are characterized by hyper-activated EGFR signaling. This is due to either 
receptor overexpression or activating mutations of the receptor [43, 47]. The FDA 
has approved pharmacological agents that antagonize ligand binding and inhibit 
EGFR kinase activity for the treatment of patients with cancers characterized by 
hyper-activated EGFR signaling [17, 108, 109]; however, these drugs have off-
target effects (i.e. colitis, corneal erosions and dermatitis) and cancers often 
become desensitized to these agents over time [110-112]. Thus, there remains a 
need to develop drugs that more aggressively and specifically target those 
cancers with enhanced EGFR signaling, but allow normal, healthy cells to 
perform biological roles. 
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One potential strategy for doing this is to hijack intrinsic signaling 
pathways and exploit them to compromise the cell’s health. Cell lines with EGFR 
overexpression either naturally (A431 and MDA-MB-468 cells [113, 114]) or via 
bioengineering (Rat-1 fibroblasts) [115], undergo EGF-induced apoptosis [43, 
119, 120]. Understanding the molecular mechanism by which this occurs will 
identify new potential pharmacological targets that can induce death in cells that 
overexpress the EGFR (i.e. cancer cells).  
Through an effector screen, STAT3 was identified as a plausible mediator 
of EGFR-induced apoptosis. Signal Transducer and Activator of Transcription 3 
(STAT3) is one of seven members of the STAT family of transcription factors, 
namely, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT7. STAT 
activation is critical for a number of biological processes, including cell 
proliferation, survival, differentiation, development and inflammation [89]. STAT3 
is a DNA-binding transcription factor that is known to mediate normal cellular 
processes upon activation by growth factors, ligands and cytoplasmic cytokines, 
such as cytokine receptor-associated Janus kinases (JAKs) [87, 88, 142, 143]. 
These upstream protein components phosphorylate STAT3 at its unique, critical 
tyrosine residues, primarily Tyr705 [87, 88]. The EGFR has also been reported to 
directly tyrosine phosphorylate STAT3 [93, 144]. STAT phosphorylation occurs at 
the cytoplasm, which induces STAT homo and heterodimer formation between 
two monomers via their Src homology 2 (SH2) domain interactions. From the 
cytoplasm, activated STAT dimers translocate and accumulate in the nucleus, 
where they initiate and mediate gene transcription by binding to DNA response 
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elements [87]. This results in either upregulation or downregulation of the 
biological effectors and subsequent cellular processes that are critical for cellular 
homeostasis. 
STAT3 has been implicated in the post-transcriptional modification of 
cellular processes, positively and negatively affecting cell growth and 
proliferation. Aberrant STAT3 signaling and constitutive activity has been 
reported in a number of cancers [89, 92].  Elevated basal STAT3 activity has 
been reported in 30-60% of primary mammary malignancies, with reports of it 
being required for tumor cell progression and metastasis [93]. However, prior to 
being implicated in cancer, STAT3-mediated programmed cellular death was 
found to be associated with and required for mammary gland involution [96, 97]. 
Additionally, STAT3 has been previously implicated as a key mediator of 
apoptosis in murine pro-B cells [145], myeloid leukemia [95], and prostate cancer 
[146]. These conflicting roles for STAT3 in the context of normal and malignant 
cellular biology highlight the need for a better understanding of this protein in 
EGFR signaling mechanisms.  
The overarching goal of this study was to identify mediators of EGFR-
mediated apoptosis. STAT3 was identified as being specifically activated under 
apoptosis-inducing conditions. Based on this finding, we develop two mutually 
exclusive hypotheses. First, STAT3 was acting as an active intermediate and 
promoting cell death, or second, STAT3 was upregulated as a compensatory 
mechanism in an attempt to promote cell survival during EGFR-induced cell 
stress. Utilizing siRNA targeting STAT3 resulted in a significant attenuation of 
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EGF-induced apoptosis. Additionally, EGFR-independent activation of STAT3 
through cytokine stimulation promoted apoptosis, as measured by PARP and 
Caspase-3 cleavage. From these findings, we conclude that STAT3 is required 
for EGFR-mediated cell death via PARP cleavage and subsequent activation.  
 
Results  
It is known that cell lines that hyperexpress the EGFR, such as MDA-MB-
468 and A431, undergo EGFR-mediated apoptosis [43, 119, 120]; however, the 
molecular mechanism(s) by which this occurs have not yet been fully elucidated. 
Previously, it has been documented that in MDA-MB-468 cells, lower 
concentrations of EGF (0.16 nM) promote cell growth, whereas higher 
concentrations (16 nM) induce apoptosis [43].  With this in mind, we screened 
MDA-MB-468 cells for the ability to activate five effector proteins that have been 
previously associated with cell growth and or apoptosis in cancer: MAPK [147, 
148], SRC [149, 150], AKT [147], BAD [151], and STAT3 [95, 152] (Figs. 4.1 and 
4.2). MDA-MB-468 cells were treated with either low (0.16 nM) or high (16 nM) 
concentrations of EGF for 0-120 minutes, and assessed the phosphorylation 
status (activity) of these effectors by immunoblot (Fig. 4.1A and Fig 4.2A). MAPK, 
SRC, AKT, and BAD displayed no significant differences in phosphorylation 
patterns with the high and low concentrations of ligand (Figs. 4.1B- E). However, 





Figure 4.1. Phosphorylation of MAPK, SRC, AKT, and BAD in response to 
high and low EGF concentrations. A. Serum-starved MDA-MB-468 cells were 
stimulated with low (0.16 nM) or high (16 nM) EGF ligand for 0-120 minutes. Cell 
lysates (20 µg) were resolved by 12% SDS-PAGE and were assessed for the 
indicated proteins via immunoblot analysis. Band intensities from the immunoblot 
data of pMAPK (B.), pSRC (C.), pAKT (D.) and pBAD (E.) were quantified, 
normalized to GAPDH levels, and plotted as the relative level compared to cells 
with no treatment. Data are expressed as the average  Standard Error of the 














(Tyrosine 705), was undetectable at all time points following stimulation with low 
concentrations of ligand, but was robustly increased over time following 
treatment with high levels of ligand (Figs. 4.2A and 4.2B). 
To determine if STAT3 phosphorylation is cell type specific, A431 cells, a 
metastatic epidermoid cell line, were employed. MDA-MB-468 and A431 cell 
lines both induce apoptosis upon EGF stimulation [120] and express comparable 
levels of EGFR [42, 153]. Like MDA-MB-468 cells, A431 cells treated with low 
concentrations of EGF did not yield significant increases in pSTAT3, but cells 
treated with high concentrations did (Figs. 4.2C and 4.2D). 
Next, we monitored STAT3 phosphorylation in MDA-MB-468 and A431 
cells following treatment with increasing concentrations of EGF ligand. Data from 
the dose-response experiments supported the findings of our time course 
experiments, displaying a dose-dependent increase in STAT3 phosphorylation in 
both cell lines (Fig. 4.3). These experiments, in two different cell lines, confirmed 
that higher concentrations of EGF were required for STAT3 phosphorylation. 
Importantly, the concentrations of EGF required for STAT3 phosphorylation were 
co-incident with the concentrations required to induce apoptosis. To further 
confirm this, EGF-beads were employed in the MDA-MB-468 cell line. Given 
previous reports of EGF-beads promoting cell growth within this cell line, we 
suspected that if STAT3 were mediating apoptosis in an EGFR dependent 
manner, we would observe preferential STAT3 phosphorylation with soluble 
EGF, and no phosphorylation with the EGF-beads. Our studies utilizing the 
beads resulted in a robust, dose-dependent increase in pSTAT3 with soluble 
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Figure 4.2. STAT3 is tyrosine phosphorylated in response to high, but not 
low, EGF concentrations. Serum-starved A. MDA-MB-468 and B. A431 cells 
were stimulated with 0.16 nM and 16 nM EGF ligand for 0-120 minutes. Cell 
lysates (20 µg and 15 µg, respectively) were resolved by 12% SDS-PAGE and 
were assessed for phospho-EGFR (pY0145), EGFR, pSTAT3 (Tyr705), STAT3 
and GAPDH, via immunoblot analysis. C. MDA-MB-468 and D. A431 immunoblot 
data were quantified, and pSTAT3 was normalized to total STAT3. Data are 




Figure 4.3. EGF phosphorylates STAT3 in a dose-dependent manner in 
MDA-MB-468 and A431 cell lines. Serum-starved MDA-MB-468 cells (A.) and 
A431 cells (B.) were treated with varying concentrations of EGF (0, 0.16, 0.5, 
1.6, 5, 16 nM) for 30 minutes. Cell lysates (40 µg) were resolved by 10% SDS 
PAGE and immunobloted for the indicated proteins. C. and D. Immunoblot data 
were quantified, and pSTAT3 was normalized to total STAT3. Data are 
expressed as the average  SEM (n=3) relative to untreated samples. 
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EGF, but no pronounced pSTAT3 in response to increasing volumes of EGF-
beads (Fig. 4.4). Our studies with the EGF-beads require us to conduct a dose-
response to determine a range of EGFR phosphorylation with the beads that 
induces comparable phosphorylation to that of soluble EGF. The bulky and larger 
size of the polystyrene bead inevitably causes steric hindrance, making it 
unfeasible to induce phosphorylation of EGFR comparable to 16 nM of soluble 
EGF. However, data from Figure 4.4 exhibit that 80 µL of EGF-beads induces 
phosphorylation of the EGFR that’s comparably to 1.6 nM of EGF, a 
concentration of soluble ligand that is still capable of inducing apoptosis in the 
MDA-MB-468 cell line [43]. In comparison to one another, the pSTAT3 bands 
that corresponds with 1.6 nM EGF is slightly darker than the corresponding band 
generated from 80 µL of EGF-beads (Fig. 4.4). These data further suggest that 
STAT3 is preferentially activated with soluble EGF, and might be associated with 
EGFR-mediated apoptosis specifically.  
 Next, to determine if the induction of STAT3 was unique for the EGFR, 
we examined another receptor family that stimulates STAT3 to see if it, too, 
promoted apoptosis. Oncostatin M (OSM) belongs to the Interleukin-6 (IL-6) 
family of cytokines [154]. Like the EGFR, it has established roles in promoting 
cancer and tumor formation in malignant prostate [155], lung, head and neck,  
and cervical [156] tissue. In addition, OSM has been shown in some cells to 
promote apoptosis [157-159]. MDA-MB-468 cells were stimulated with 100 ng/mL 




Figure 4.4 STAT3 is preferentially upregulated with soluble EGF, and not 
with EGF-beads. MDA-MB-468 cells were stimulated with the indicated 
concentrations of soluble EGF (nM) and volumes of EGF-beads (µL) for 30 
minutes. Cells were then rinsed and lysed as previously describe. Cell lysates 


















cleavage (Fig. 4.5).  In addition to stimulating pSTAT3, OSM activated pVASP, a 
substrate of PKG as well as apoptotic pathways (as evident by increases in 
cleaved PARP and cleaved Caspase-3)(Fig. 4.5A). Quantification of multiple 
assays indicates that OSM-induced PARP cleavage (Fig. 4.5B) and Caspase-3 
cleavage (Fig. 4.5C) is comparable to that induced by EGF. Upon exposure to 
STS, STAT3 activation was not induced (Fig. 4.5D). Together, these data are 
consistent with the hypothesis that multiple cell surface receptors induce STAT3 
phosphorylation co-incident with apoptotic pathways. 
 Having established that STAT3 phosphorylation correlates with high 
concentrations of EGF ligand, and preferentially with soluble EGF ligand, we 
hypothesized that EGFR-mediated apoptosis occurred in a STAT3-dependent 
manner (Fig. 4.6A). On the contrary, STAT3 could have been have been 
upregulated with high ligand stimulation as a compensatory mechanism, in a 
failed attempt to rescue the cells from an EGFR-mediated apoptotic fate (Fig. 
4.6B). To distinguish between these two possibilities, we antagonized STAT3 
with pharmacological inhibitors, Stattic and S3I-201, and then stimulated MDA-
MB-468 and A431 cells with EGF (Figs. 4.7 and 4.8). These cells were assessed 
for cell viability and for their ability to induce apoptotic pathways. Caspase-3 is a 
well-established executioner of apoptosis [129]. Upon its cleavage and 
subsequent activation, it cleaves and activates other downstream effectors that 
promote the induction of apoptosis (i.e. poly ADP-ribose polymerase or PARP). If 






Figure 4.5 EGFR-independent activation of STAT3 promotes apoptosis in 
MDA-MB-468 cells.  A. Serum-starved MDA-MB-468 cells were stimulated with 
100 ng/mL of Oncostatin M (OSM) for the indicated times. Control cells were 
exposed to serum free DMEM (SF) and or 16 nM EGF for 24 hours. After 
harvesting, the cell lysates (40 µg) were resolved by SDS PAGE, and were 
immunoblotted for the indicated proteins. Densitometry quantification of western 
blot data of cleaved PARP (B.) and cleaved Caspase-3 (C.). The cleaved PARP 
band intensities were normalized to and plotted as a percentage of total PARP 
bands. Cleaved Caspase-3 bands were quantified to total protein for each 
respective sample (GAPDH).  Data are expressed as the average  SEM (n=3). 
D. Serum-starved MDA-MB-468 cells were stimulated with 3, 10, 30, or 100 nM 
Staurosproine (STS) for 4 hours. Control cells were exposed to serum free 
DMEM (SF) and or 16 nM EGF for 4 hours. Cell lysates (40 µg) were resolved by 












Figure 4.6. Models of STAT3 Activity and its potential role(s) in EGFR-
mediated Apoptosis. Model A depicts STAT3 playing a direct role in mediating 
EGF-induced apoptosis. Contrastingly, model B depicts STAT3 playing a 
compensatory role to promote cellular growth to prevent an EGFR-mediated 





































and Caspase-3 cleavage, coincident with enhanced viability in STAT3 
antagonized cells. Conversely, if STAT3 were being activated as a compensatory 
mechanism, inhibition of STAT3 would not affect induction of the apoptotic 
pathways and would likely further decrease cell viability. 
Upon exposure to both inhibitors, cell viability analyses revealed a dose- 
dependent decrease in viability in both MDA-MB-468 and A431 cells, 
independent of the presence of EGF (Figs. 4.7A, 4.7C, 4.8A, 4.8C). Although 
Stattic was more potent than S31-201, and MDA-MB-468 cells were more 
sensitive to inhibitor treatments than A431 cells, the trends held in both cell lines. 
Complementary with the viability data, we observed a dose-dependent increase 
in cleaved PARP and cleaved Capsase-3 phosphorylation. This finding was 
observed in both cell lines when cells were treated with 16 nM EGF in 
combination with the STAT3 inhibitors. However, coincident with a dose-
dependent decrease in phosphorylated STAT3, both cell lines displayed a 
corresponding decrease in EGFR phosphorylation (Figs. 4.7B, 4.7D, 4.8B, and 
4.8D).  
We wanted to determine whether these decreases in cell viability were 
due to STAT3 inhibition or from a toxicity mediated by the compounds 
themselves. To assess whether the compounds were inherently cytotoxic, we 
employed the PC3 cell line, a prostatic carcinoma cell line lacking STAT3 
expression [146]. Our biochemistry analysis confirmed that PC3 cells do not 
express STAT3 and have very low levels of EGFR expression (Fig. 4.9A). PC3 









Figure 4.7. STAT3 inhibitors attenuate cell viability and EGFR activity in 
MDA-MB-468 cells. MDA-MB-468 cells, plated and treated in parallel, were 
assessed for cell viability using an Alamar Blue assay. Data from A. Stattic or C. 
S31-201 treated cells are expressed as the average  SEM (n=3) relative to 
cells treated without serum (SF). Serum-starved cells were pre-treated for 1 hour 
with 0 (0.025% DMSO), 0.3, 1, 3, 5, or 10 µM Stattic (IC50 = 5.1 µM; panel B.), or 
with 0 (0.5% DMSO), 1, 3, 10, 30, and 100 µM S3I-201(IC50 = 86 µM; panel D.), 
followed by the addition of 16 nM EGF (+) for 24 hours. Control cells were 
incubated with serum free media alone (SF), media containing 10% fetal bovine 
serum (FBS), or 16 nM EGF (EGF) for 24 hours. As a positive control cells were 
treated with 1 µM staurosporine (STS) for 4 hours. Cell lysates were prepared 
and 40 µg were resolved by SDS-PAGE before being assessed for the indicated 
proteins. For STS treated samples, 15 µg of cell lysates were loaded to keep the 
















Figure 4.8. STAT3 inhibitors attenuate EGFR activity in A431 cells. A431 
cells, plated and treated in parallel, were assessed for cell viability using an 
Alamar Blue assay. Data from A. Stattic or B. S31-201 treated cells are 
expressed as the average  SEM (n=3) relative to cells incubated in 1.25% FBS 
in DMEM (reduced serum – RS). Serum-starved A431 cells were pre-treated for 
1 hour with 0 (0.025% DMSO), 0.3, 1, 3, 5, or 10 µM Stattic (IC50 = 5.1 µM; panel 
A.), or with 0 (0.5% DMSO), 1, 3, 10, 30, and 100 µM S3I-201 (IC50 = 86 µM; 
panel C.), followed by the addition of 16 nM EGF (+) for 24 hours. Control cells 
were incubated with reduced serum media alone (RS), media containing 10% 
fetal bovine serum (FBS), or 16 nM EGF (EGF) for 24 hours. As a positive 
control cells were treated with 1 µM staurosporine (STS) for 4 hours. Cell lysates 
were prepared, 40 µg were resolved by SDS-PAGE, and immunoblotted for the 
indicated proteins. Fifteen µg of the STS sample were used to keep the 
immunoblot analysis in the dynamic range. Shown is a representative 








viability upon stimulation with Stattic and S3I-201 (Fig. 4.9B). These data indicate 
the STAT3 inhibitors had off-target activity, and an alternative method was 
needed to attenuate STAT3 activity and determine its ultimate role in EGFR-
mediated apoptosis.   
Next, we employed STAT3 siRNA as a more selective mode of reducing 
STAT3 expression in the MDA-MB-468 cell line (Fig. 4.10). As compared to 
control siRNA (siCON), STAT3 reduced STAT3 expression by 78% (Fig. 4.10A). 
STAT3 knock down cells were slightly more viable than control cells following 
treatment with the high concentrations of EGF required to induce apoptosis (Fig. 
4.10B). Biochemically, STAT3 knock down cells had reduced EGF-induced 






Figure 4.9. STAT3 inhibitors reduce cell viability in STAT3-null, PC3 cells.  
A. Serum-starved MDA-MB-468 and PC3 cells were treated with either DMEM 
alone (-), or DMEM supplemented with 16 nM EGF (+) for 1 hour. Cell lysates (20 
µg) were resolved by 10% SDS PAGE, and immunoblotted for the indicated 
proteins. Shown is a representative experiment repeated three times. B.  PC3 
cells were exposed to treatments of serum free media (SF), DMEM with 0.025% 
DMSO (0), 1, 5, 10 µM Stattic; 0.5% DMSO (0), 1, 10, 100 µM S31-201; or 168 
nM Staurosporine (STS) for a total of 24 hours. Cell viability was assessed with 
an Alamar Blue assay.  Data are normalized to cell viability in serum free media 





















Figure 4.10. Knockdown of STAT3 attenuates EGFR-mediated apoptosis in 
MDA-MB-468 cells.  A. MDA-MB-468 cells were transfected with either 200 nM 
control siRNA (siCON) or 200 nM STAT3 siRNA for 72 hours. Cell lysates were 
prepared, and decreasing protein concentrations (40, 20, and 10 µg) were 
resolved by 10% SDS PAGE and immunoblotted for EGFR, STAT3, and 
GAPDH. B. Fourty-eight hours post-transfection, siCON and STAT3 siRNA-
transfected cells were treated for 24 hours with 0 (SF), 0.16, 1.6, 16 nM EGF or 
168 nM Staurosporine (STS) as a positive control. Cell viability was assessed by 
an Alamar Blue assay. Data are expressed as the average  SEM (n=3). C. 
Cleaved PARP and cleaved Caspase-3 were assessed in siCON and STAT3 
siRNA transfected cells. Seventy-two hours post-transfection, cells were 
coincidently exposed to SF DMEM and 16 nM EGF for 24 hours or 1 µM STS for 
4 hours prior to harvesting. Cell lysates (40 µg) were resolved on either a 10% 
SDS PAGE (pY1045, PARP, and GAPDH) or a 15% SDS PAGE (pSTAT3 and 
cleaved Caspase-3), and were assessed for the indicated proteins via 
immunoblot analysis. Densitometry quantification of western blot data of cleaved 
PARP (D.) and cleaved Caspase-3 (E.). The cleaved PARP band intensities 
were normalized to and plotted as a percentage of total PARP. The intensity of 
cleaved Caspase-3 was normalized to the levels of GAPDH.  Data are expressed 







EGFR-mediated apoptosis is a paradox for growth factor receptors. 
However, dissecting how a receptor that normally mediates cell growth and 
proliferation induces cell death when overexpressed provides an opportunity to 
understand receptor signaling and develop strategies for attenuating the growth 
of cancer cells with elevated EGFR levels. In this study, we assessed effector 
candidates with documented affiliation with EGFR activation [147, 150, 160] and 
implication in human malignancies by either promoting proliferation [147, 148, 
152, 161] and/or attenuating it [95, 148, 149, 151]. We assessed MAPK, SRC, 
AKT, BAD, and STAT3 for phosphorylation following treatment with low (0.16 
nM) versus high (16 nM) concentrations of EGF (Figs. 4.1 and 4.2). Among 
these, only STAT3 was activated when ligand concentrations were sufficient to 
induce the apoptotic pathways. This was not only true for the EGFR, but 
cytokine-mediated activation of STAT3 via OSM resulted in the induction of 
apoptosis as well (Fig. 4.5).  
Pharmacological inhibitors of STAT3 were employed to ascertain the role 
of STAT3 on EGFR-mediated apoptosis. As expected, STAT3 inhibitors in MDA-
MB-468 and A431 cells resulted in a dose-dependent decrease in STAT3 
phosphorylation. Unexpectedly, these inhibitors also antagonized EGFR 
phosphorylation and decreased cell viability (Figs. 4.7 and 4.8). This cytotoxicity 
cannot be attributed only to STAT3 inhibition; STAT3-null, PC3 cells were also 
less viable in response to these inhibitors (Fig. 4.9). RNAi proved to be a more 
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useful tool for studying the role of STAT3. Knock down of STAT3 with siRNA 
significantly attenuated EGF-induced PARP cleavage and also reduced 
Caspase-3 cleavage and cell death (Fig. 4.10). These data provide evidence that 
support STAT3 as a direct mediator of EGF-induced apoptosis. 
Since it was first reported by Armstrong et al in 1994 [162], the molecular 
mechanism by which EGFR-mediated apoptosis occurs has remained 
controversial. A number of signaling molecules have been reported to be 
involved in this process including Etk [163], STAT1 [164], Caspase-1 [48], and 
Protein Kinase G [165].  Dissecting the signaling events that emanate from a 
hyperexpressed receptor and culminate in cell death are challenging for a 
number of reasons. First, high levels of receptors are going to favor the formation 
of receptor:effector complexes that may not occur with physiological levels of 
receptor expression. Second, cells with elevated receptor expression have 
altered kinetics of receptor down regulation through the endocytic pathway [166, 
167]. In cells with physiological levels of receptor expression, the EGFR will 
traffic to the lysosome for degradation; in MDA-MB-468 cells, the activated EGFR 
internalizes to the early endosome and can be retained there for 24 hours [168]. 
This increases the duration of total receptor activity, as well as any 
receptor:effector interactions in the early endosome. Finally, the kinetics of 
EGFR-mediated apoptosis provide a large window (0-16 hours) to monitor the 
many effectors activated by the receptor. 
Despite these limitations to studying apoptosis, we were able to identify a 
role for STAT3. There are multiple lines of evidence that support this role. First, 
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the concentrations of EGF needed to activate STAT3 in MDA-MB-468 and A431 
cells (Fig. 4.3) are consistent with the concentrations of EGF required to induce 
apoptosis. Second, the kinetics of EGFR-mediated apoptosis (over the course of 
16-48 hours [44, 165]) are consistent with a transcriptionally regulated event. 
Third, STAT3 is a well-documented regulator of cell growth, albeit more 
frequently having a positive effect. STAT3 has been associated with proliferative 
activity in numerous malignancies, including glioblastoma [169], non-small cell 
lung [170], and colorectal cancer [171]. In addition, STAT3-induced 
tumorigenesis is linked to its constitutive activity in certain cancer cells [172-174]. 
Constitutive STAT3 activity was not observed in our MDA-MB-468 or A431 cells 
(Figs. 4.2 and 4.3). In addition, there are data, consistent with ours, which 
contradict these findings and implicate STAT3 as a mediator of cell death [175-
177].  
The contradiction between our experimental results regarding STAT3 
activity under pro-apoptotic conditions and the published data regarding the pro-
growth events of STAT3 led us to propose two opposing hypothesis. The first 
hypothesis was that STAT3 is a mediator of apoptosis and that inhibition of the 
protein would enhance cell viability. The second hypothesis was that the 
induction of STAT3 activity was a compensatory reaction to the induction of 
apoptosis promoted by another pathway (Fig. 4.6). Our subsequent experiments 
indicate that STAT3 mediates apoptosis and is not a compensatory mechanism.  
Previous reports have shown that the EGFR kinase directly activates 
STAT3 [90], and that is likely the case in the MDA-MB-468 and A431 cells, 
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particularly based on the kinetics of STAT3 phosphorylation. Given these 
interactions require high doses of EGF and high receptor levels, this is likely a 
pathological event rather than a physiological.  
How STAT3 progresses to apoptosis is more ambiguous. It has been 
previously reported that STAT3 activity directly promotes apoptosis in some 
cancers [95, 146, 178, 179], and suppresses cancer cell colony formation and 
invasion [180]. One possibility is that in MDA-MB-468 cells, like LNCaP cells, 
STAT3 transcription is causing growth arrest and a block in cell cycle progression 
[146]. This, coupled with strong proliferative EGFR signals, may result in a 
signaling conflict for the cell that results in an apoptotic response. A second 
option is that the high levels of STAT3 phosphorylation may increase the 
magnitude and/or duration gene transcription that disrupts cell homeostasis and 
causes cell death. Alternatively, high levels of activated STAT3 may lead to 
aberrant STAT heterodimer formation. Previous studies have reported a role for 
STAT1 in the induction of apoptosis [148, 164, 181]. More specifically, STAT1 
has been implicated in EGFR-mediated apoptosis in A431 cells [138, 164] and 
MDA-MB-468 cells [163]. Increased STAT3 activity may drive STAT1:STAT3 
heterodimer formation which in turn allows STAT1 to drive apoptosis. 
These changes in signaling may reflect mis-regulation of a normal 
physiological process. STAT3-mediated apoptosis occurs during mammary gland 
involution [96, 97], a complex process that returns mammary tissue to its pre-
lactation, morphological state [182]. The initiation of this process is dependent on 
the presence of milk in the alveoli after weaning, which elicits the synthesis of 
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cytokines and growth factors that activate the STAT3 pathway to then 
subsequently induce apoptosis [183-185]. The high concentrations of EGF ligand 
in milk [186] are indirect evidence that point to the EGFR’s role within this 
process. EGF-induced STAT3 activity and the subsequent induction of apoptosis 
in MDA-MB-468 cells may therefore employ the same molecular mechanisms 
required for mammary gland involution. Kreuzaler et al. have reported that 
STAT3-mediated apoptosis in mammary gland involution entails enhancing 
cathepsin B and L activity, while also downregulating their endogenous inhibitor, 
serine protease inhibitor 2A (spi2A), in a process that occurs independently of 
caspase 3, 6 and 7 activity [187]. Similarly, our data indicate that caspase 3 is 
not a major factor in EGF-induced, STAT3-mediated apoptosis in MDA-MB-468 
cells.  Together, the cathepsin proteases, spi2A, and other effectors implicated in 
mammary gland involution may be worth assessing in the context of EGF-
induced, STAT3-mediated apoptosis (Depicted in Fig. 4.6A).  
Another plausible explanation for this phenomenon is the pathway in 
which cell death is induced. Caspase-1 activation promotes a particular form of 
cell death that results from inflammatory responses, in a process known as 
pyroptosis [188]. Pyroptosis has been documented to induce DNA fragmentation 
[189] and has also been shown to cleave and activate PARP [68]. Given that 
Caspase-1 inhibition is capable of blocking EGFR-mediated cell death in MDA-
MB-468 cells [48], pyroptosis may be an additional mode of cell death employed 
by the EGFR. In addition to eliciting STAT3 activity, the Interleukin family of 
cytokines has been well documented to promote inflammation and further 
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progress inflammatory diseases [190-192]. Interferon-beta, a member of the 
interferon family of cytokines, promotes apoptosis in pro-B cells in a STAT3-
dependent manner [145]. Thus, EGF-induced STAT3 activation and the 
subsequent induction of pyroptosis would not be an unexpected finding.  
These signaling differences must also be considered in the context of the 
subcellular location in which they occur.  There has been a well-established role 
for spatial regulation of EGFR signaling by the endocytic pathway [193]. In MDA-
MB-468 cells, retention of the activated EGFR on the plasma membrane 
promotes cell proliferation whereas when the EGF:EGFR complex internalizes 
the cell undergoes apoptosis [44]. Further, the induction of apoptotic pathways is 
linked to the endosomal accumulation of the EGF:EGFR complex [168]. Since 
high concentrations of ligand are required for apoptosis, one must consider the 
contribution of different routes of EGFR internalization. Sigismund et al. have 
shown that low EGF ligand stimulation (1.5 ng/mL) primarily results in a clathrin-
mediated manner of EGFR internalization, whereas high ligand stimulation (20 
ng/mL) promotes a clathrin-independent, lipid raft-mediated mode of endocytosis 
[22]. These differing routes may also impact the composition of EGFR-containing 
endosomes and which down stream signaling molecules are present. 
Although all models are possible, in summarizing the literature, we favor 
the notion that apoptosis results from the convergence of multiple signaling 
events. Hyper-activated signaling, due to an increased number of active 
receptors coupled with slowed down regulation, results in increased metabolic 
and proliferative cell biology. The cell cannot accommodate these demands, 
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resulting in a disrupted cellular homeostasis that cannot be restored. Ultimately, 
the cell succumbs due to the stress of the saturated endocytic pathway. While 
this does not identify a specific, pharmacological target, it suggests the potential 






SUMMARY AND FUTURE DIRECTIONS 
 
A. Restatement of Research Goals 
 
 The goal of the work described throughout this dissertation was to 
elucidate the underlying mechanisms required for EGFR-mediated apoptosis to 
occur. The paradox of EGFR-mediated cell growth versus EGFR-mediated 
apoptosis is uncertain, and has remained so for decades. Identifying the 
signaling effectors with direct implications in receptor-mediated apoptosis not 
only contributes to the discipline of cellular biology, but also establishes a new 
mode of therapeutically targeting cancers that are characterized by receptor 
hyperexpression.  
 
B. Summary of Findings 
 
We have identified two signaling molecules, which both have shown to 
promote EGF-induced apoptosis. In Chapter III, we assessed and defined PKG 
in this cellular process. Previous reports have implicated PKG activation as a 
mediator of cell death in MDA-MB-468 cells, generally [86, 99]. Given this 
information, we hypothesized that PKG might be mediating  
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EGF-induced apoptosis, downstream, or possibly upstream of EGFR activation. 
To differentiate between these two possibilities, we stimulated MDA-MB-468 cells 
with agonists of PKG (8-Br-cGMP and 8-pCPT-cGMP-AM), and assessed for 
phosphorylated EGFR. We also stimulated cells with EGF and assessed for a 
substrate of PKG, phosphorylated VASP(Ser239). We found that the PKG 
agonists did not elicit EGFR phosphorylation, where on the contrary, EGF ligand 
induced PKG activity in a dose dependent manner. EGF-induced PKG 
stimulation was confirmed in multiple cell lines (A431 and HeLa), further 
supporting the notion that EGFR did in fact activate PKG, and PKG activity 
selectively occurred downstream of receptor activation.  
RNAi targeting PKG, and subsequent stimulation of EGFR resulted in a 
significant attenuation of cell death, accompanied with a non-significant 
attenuation of apoptosis, as measured by PARP and Caspase-3 cleavage. The 
modesty in these findings may be attributed to the transfection efficiency of the 
PKG siRNA (55%), which is consistent with previous reports [130], but 
nonetheless marginal. From these data, we concluded that PKG is a mediator of 
EGF-induce apoptosis in MDA-MB-468 cells, but not a very critical one.  
To identify effectors with more pertinent roles in EGFR-mediated 
apoptosis, we began in Chapter IV by subjecting MDA-MB-468 cells to a 
thorough effector screen, assessing the phosphorylation pattern of effectors that 
are well-established substrates of the EGFR (MAPK, Src, AKT, BAD, and 
STAT3). We subjected MDA-MB-468 cells to conditions in which the cells 
undergo EGFR-mediated cell growth, and conversely EGFR-mediated apoptosis, 
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and assessed the phosphorylation patterns of these five effectors for their 
potential association with one of these two conditions, preferentially. STAT3 
activity was the only effector with a preferentially robust increase in 
phosphorylation at conditions that coincidently induce apoptosis.  
Our findings helped develop the hypothesis that STAT3 was a mediator of 
EGF-induced apoptosis. Given the many reports depicting STAT3 portraying a 
pro-proliferative role in cancer [169-171], we developed the alternative 
hypothesis that STAT3 upregulation was the result of a compensatory 
mechanism, in an attempt to rescue the cell from EGFR-mediated apoptosis. 
Logically, in order to assess both of these hypotheses, we needed to abrogate 
STAT3 activity and or gene expression, activate the EGFR, and subsequently 
assess the outcome of this on receptor-mediated apoptosis. A rise in viability and 
an ultimate attenuation of apoptosis would favor the notion of STAT3 as a 
mediator of EGF-induce apoptosis; similar to our findings with PKG. On the 
contrary, observing an increase in apoptosis, and a further reduction in viability 
would define the role of STAT3 in pro-proliferative, compensatory signaling 
cascade.  
We began our investigation by employing commercially available 
antagonists of STAT3, Stattic and S3I-201. Inhibitor treatments in the presence 
of EGF resulted in a dose dependent decrease in MDA-MB-468 and A431 cell 
viability. Biochemical analyses of the inhibitor treatments in the presence of EGF 
resulted in a dose dependent increase in apoptosis, which appeared to be 
substantially greater than in cells treated with EGF alone. Together, these 
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findings favored our “pro-proliferative, compensatory” STAT3 hypothesis. 
However, further assessment of the inhibitor biochemistry revealed that with a 
dose dependent decrease in STAT3 activity, EGFR phosphorylation was 
coincidently decreased as well.  We concluded that this was due to one of two 
possibilities. Either the STAT3: EGFR complex entailed a tightly coupled 
relationship between the two proteins, resulting in a dual-inhibitory effect, or 
these STAT3 antagonists were exhibiting off-target, non-specific cytotoxicity. The 
first possibility was not favored, considering previous reports that have indicated 
a low affinity of STAT3 for EGFR in both A431 and MDA-MB-468 cells [194]. The 
second possibility seemed more likely, given that our viability data showed no 
attenuation of inhibitor with EGF treatment in comparison to EGF treatment 
alone. Therefore, we hypothesized that Stattic and S3I-201 were exhibiting off-
target effects, in vitro. 
 To determine if the STAT3 inhibitors were in fact non-specifically cytotoxic, 
we employed the PC3 cell line, which contains very low EGFR expression, and is 
completely void of STAT3. A cell line without STAT3 expression biochemically 
functions and maintains cellular homeostasis independent of STAT3 activity. 
Therefore, the addition of these STAT3 antagonists to the PC3 cells should result 
in no deleterious effects on cell viability. The PC3 cell line however did exhibit a 
dose dependent decrease in cell viability as a result of the STAT3 inhibitors. The 
Stattic inhibitor was shown to be very cytotoxic (consistent within the MDA-MB-
468 and A431 cell lines), more than our positive control for cell death, STS. 
Additionally, the lack of STAT3 expression and low level EGFR expression in 
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PC3 cells further suggests that these inhibitors promote their cytotoxic effects 
through multiple, unknown pleiotropic mechanisms. Although these studies did 
not contribute any further insight to the cellular mechanism of STAT3 activity in 
EGFR-mediated apoptosis, they are a paramount contribution in terms of the use 
of the clinical use of STAT3 antagonists. STAT3 inhibitors have been well 
documented to be clinically beneficial in the treatment of cancer [195-197] and 
muscle degeneration [198, 199]. In addition to proving their limitations, our 
reports of STAT3 antagonist-induced, off-target interactions suggest the use of 
caution in regard to their therapeutic administration.  
Continuing on within our research, we elected to employ STAT3 siRNA as 
a more selective mode of abrogating STAT3 activity in the MDA-MB-468 cell line. 
STAT3 knock down cells displayed a significant reduction in EGFR-mediated 
apoptosis, as measured by PARP cleavage. Although Caspase-3 cleavage was 
also attenuated, the results were however statistically insignificant. Nonetheless, 
these data strongly depicted STAT3 as a critical mediator of EGF-induced 
apoptosis, via PARP activation.  
To further strengthen our findings, we decided to assess STAT3 activity 
independent of EGFR-activation. First, we subjected MDA-MB-468 cells to a 
cytokine (OSM) that has been documented to induce STAT3 activation. The 
results of these studies indicate that with a simultaneous activation of STAT3, a 
sustained increase in PARP and Caspase-3 cleavage was also observed over 
time. In addition to STAT3 activation, OSM induced a time-dependent increase 
pVASP stimulation. This further supported STAT3 as a mediator of apoptosis, 
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while also suggesting it does so through activation of our initial effector 
candidate, PKG. In our final assessment if STAT3, we stimulated MDA-MB-468 
cells with concentrations of STS capable of inducing cell stress without causing 
catastrophic cellular damage. Our goal was to establish whether or not STAT3 
activity was induced in response to cell stress generally, and also to determine if 
STAT3 activation could be achieved independently of cytokine or growth factor 
mediation. The results displayed no induction of STAT3 activity with STS 
activation, suggesting that cytokine or growth factor activation is required to 
simulate STAT3 and promote its apoptotic effects. In summary of Chapter IV, our 
data provide evidence of a novel, molecular interaction between EGFR and 
STAT3, with EGFR requiring STAT3 to exert its apoptotic effects in MDA-MB-468 
cells. 
 
C. Significance of Findings 
 
The significance among this research lies within the identification of key, 
molecular links in-between initial EGFR activation and the ultimate induction of 
apoptosis.  PKG and STAT3 differ both structurally, and in terms of their 
physiological implications. However, both of these effectors contribute to an 
EGF-induced apoptotic fate in MDA-MB-468 cells. Although PKG has shown to 
play a more minor role in receptor-mediated cell death, preliminary data suggests 
that STAT3 may signal to and stimulates PKG and subsequent pVASP activity 
(Figure 4.4) Not only does this support the roles of PKG and STAT3 in promoting 
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receptor-mediated apoptosis, but it also provides some insight in terms of their 
correlation, and the sequence of their signaling within this subcellular 
mechanism.  
The role of STAT3 in tumor cell formation has been well established both 
within the literature and this dissertation. This has been shown to be due to 
constitutive activation of STAT3 in certain cancer cell lines [172-174]. The MDA-
MB-468 cell line is among those documented to exhibit constitutive STAT3 
activity [88, 200]; however, consistent with our findings, some studies have 
shown that STAT3 is not constitutively active in MDA-MB-468 cells [175-177]. 
The discrepancy among these results remains inexplicit. In regard to our 
research, we employed low-passage MDA-MB-468 cells, which were stringently 
restricted from long-term propagation. In addition, we thoroughly optimized and 
executed proper conditions for serum starvation for each of the cell lines of use. 
Although these practices are quite simple by nature, they are pivotal in the proper 
maintenance of a tissue culture cell line in order to avoid cellular transformation. 
Each of these components may be a plausible explanation for the contradictory 
reports of STAT3 constitutive activity in MDA-MB-468 cells.  
Our findings identify a minor mediator (PKG) and a more prominent 
mediator (STAT3) of EGF-induced cell death and apoptosis. In addition to 
expanding the knowledge to the mechanisms of EGFR-mediated apoptosis, this 
research suggests that the addition of PKG and or STAT3 agonists might 
increase the efficacy of current cancer therapeutics that target EGFR-
overexpressed cancers.  
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D. Strengths and Weaknesses 
 
 1.  Strengths 
There are several strengths of the research described in this dissertation. 
The first being the sensitivity and specificity of western blotting. As low as 20 ng 
of protein can be resolved on an SDS PAGE and still detected upon immunoblot 
analyses [201]. Additionally, the antibody-antigen interaction provides a very 
specific mode of protein identification, which when properly optimized, provides 
results with very minimal cross-reactivity upon assessing proteins of similar sizes 
[202].   
The unambiguous readout of studies that assess subcellular signaling 
mechanisms is another advantage of this project. Thorough identification of 
proteins and their roles in signaling cascades does not elicit much doubt or 
possibility of multiple interpretations. It is possible that a particular protein may be 
employed in multiple, non-correlated signaling cascades; however, through the 
use of pharmacological inhibitors and or RNAi, it is feasible to distinguish 
whether or not that particular protein is a critical mediator in a pathway of 
interest. Within this project specifically, this was advantageous in regard to our 
experimental hypotheses. Had our initial hypothesis (in our assessments of both 
PKG and STAT3) proven to be incorrect, our hypotheses were excellently 
designed in such a manner that the alternative outcome would have still provided 
novel contributions to the discipline of receptor biology.  
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2. Weaknesses  
The use of a tissue culture model system does have some limitations. It is 
useful in terms of conducting preliminary work; however, this model does not 
take into account the complexity of an entire living organism. Although our 
findings that PKG and STAT3 attenuate human breast cancer cell growth, they 
both may possibly exhibit unintended, deleterious affects in other tissue. A major 
progression within this study and project would be to assess our findings in a 
more molecularly complex organism.  
Another weakness of this work lies in the lack of variation among the 
assays employed, more specifically in terms our analyses of apoptosis. The use 
of more diverse and quantitative assays to assess apoptosis would have 
definitely strengthened our data and overall conclusions. We did attempt to 
employ more quantitative apoptotic assays, including: Annexin V (BD 
Pharmingen, Franklin Lakes, NJ), which asseses for Phosphatidylserine 
translocation; ApoStrand ELISA (Enzo, Farmingdal, NY), which assess single 
strand DNA in apoptotic cells; and a Caspase- 3/7 Assay kit (Anaspec, Fremont, 
CA), which assesses the kinetics of Caspase-3 and Caspase-7 activity. Upon 
employing all of these assays, we observed no significant induction of apoptosis 
in our EGF treated MDA-MB-468 cells, coincident with a substantially high 
induction of apoptosis in our serum free, viable cells. This may be attributed to 
employing a sample size below the limit of detection or the need for further assay 
optimization. Reports have shown that in cell lines with high EGFR and Erb-B2 
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expression, EGFR-mediated apoptosis induced marginal Caspase-3 activation 
[132]. Our Caspase-3 cleavage data are consistent with this report, which 
suggests that Caspase-3 may not be critical mediator in EGF-induced apoptosis. 
Therefore, there may be other modes of cell death employed to achieve an 
EGFR-mediated apoptotic fate. These modes and the respective assays to 
assess them are components that will need to be considered in order to further 
progress this project.  
Although the defect in EGFR trafficking provides an excellent model to 
study receptor signaling from the endosomes, this does however present some 
limitations. In MDA-MB-468 cells, the activated EGFR accumulates on the 
limiting membrane of the early endosome, and can be retained there for up to 24 
hours [45]. This increases the duration of receptor activity while also providing a 
relatively large window for receptor-mediated apoptosis to occur. Due to this, it 
was challenging to determine the most optimal time points to assess EGFR-
mediated apoptosis and the effectors that were implicated with it.  
 
E. Future Directions  
 
 This work has elucidated some of the signaling mechanisms that are 
implicated in EGF-induced apoptosis. However, this has inevitably raised more 
questions, requiring additional assessments to progress this project and to 
further expand upon the molecular mechanisms of receptor-mediated apoptosis. 
The first approach in progressing this project entails assessing PKG and STAT3 
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activity relative to one another in MDA-MB-468 cells. Data from chapter IV 
suggest that EGFR-independent STAT3 activity elicits downstream activation of 
PKG prior to the ultimate induction of apoptosis. It would be interesting to confirm 
if STAT3 is in fact upstream and necessary for PKG activation to occur. Doing so 
would require PKG inhibition, and subsequent stimulation of STAT3 activity (with 
OSM), prior to ultimately assessing VASP phosphorylation. Following this, it 
would be interesting to assess PKG and STAT3 dual-knock down, and the 
ultimate outcome of this on EGFR-mediated apoptosis in MDA-MB-568 cells. 
Observing an even greater attenuation of apoptosis in cells with impaired PKG 
and STAT3 activity would further confirm their roles in receptor-mediated 
apoptosis, and would also define the correlation between PKG-induced and 
STAT3- induced cell death signaling pathways.  
The next approach involves assessing the defect in EGFR trafficking 
observed in the MDA-MB-468 cells. It is our belief that the slowed kinetics of 
receptor degradation within this cell line is the more critical underlying culprit 
behind EGFR-mediated apoptosis. The EGFR has been shown to accumulate on 
the limiting membrane of the early endosome in these cells [45]. In addition to 
increasing the duration of total receptor activity, this defect also initiates the 
induction of apoptosis at the early endosome. This is suspected to be due to the 
saturation of the endocytic pathway, which subsequently induces cell stress. 
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a 
phosphatase that belongs to the subclass of dual-specificity enzymes. It is 
capable of dephosphorylating serine, threonine or tyrosine residues on protein 
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targets [203]. In addition, PTEN has been shown to be necessary to promote 
EGFR trafficking from early to late endosomes [204], and has been shown to be 
void in MDA-MB-468 cells [205]. Expression of PTEN into MDA-MB-468 cells 
resulted in ligand-induced degradation of EGFR [204]. Additionally, genetic 
deletion of STAT3 and PTEN has been shown to trigger tumor progression in a 
mouse model for prostate cancer [180], suggesting a co-dependency among 
these proteins in terms of their role in cancer progression. If we were to transfect 
PTEN into MDA-MB-468 cells, while simultaneously knocking down STAT3 (and 
PKG), it would be interesting if we could enhance the kinetics of EGFR trafficking 
and simultaneously reduce the rate of receptor-mediated apoptosis. This would 
not provide a major contribution in terms of the cancer biology aspect of this 
project, but it would however further reveal additional components that contribute 
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